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Abbreviations and symbols 
 
AA  amino acid 
AbD   assay(s) by design (Applied Biosystems, available at 
https://www.store.appliedbiosystems.com) 
AGR2  human homologues anterior gradient proteins 2 
AGR3  human homologues anterior gradient proteins 3 
AoD   assay(s) on demand ( Applied Biosystems, available at 
https://www.store.appliedbiosystems.com) 
ASP  affected sibling pair 
bp   base pairs 
CD   Crohn's disease 
cDNA   complementary DNA 
cM   centiMorgan 
CU   Colitis ulcerosa 
°C   degree Celsius 
χ2   chi-square, measure of association or independence 
D'   D prime (measure of LD) 
dATP   2'-deoxyadenosine-5'-triphosphate 
dCTP   2'-deoxycytidine-5'-triphosphate 
DDW   double-distilled water 
dGTP   2'-deoxyguanosine-5'-triphosphate 
DNA   deoxyribonucleic acid 
dNTP   2'-deoxynucleotide-5'-triphosphate 
dsDNA  double-stranded deoxyribonucleic acid 
dTTP   2'-deoxythymidine 5'-triphosphate 
EDTA   ethylenediaminetetraacetic acid 
FAM   6-carbofluorescein 
Fig.   figure 
Figs   figures 
g   gram(s) 
xg   relative centrifugal force (RCF) 
h   hour(s) 
HWE   Hardy-Weinberg-Equilibrium 
IBD   Inflammatory bowel disease 
ibd   identity by descent 
ibs   identity by state 
IFN   interferon (e.g. IFN-g) 
kb   kilobase 
kD   kilodalton 
l   liter(s) 
LD   linkage disequilibrium 
LDU   linkage disequilibrium units 
LOD   logarithm of odds 
M   molar (mol/l) 
Mb   Mega base 
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mg   milligram(s) 
min   minute(s) 
ml   millilitre(s) 
MLE  maximum likelihood estimate 
mM   millimolar (mmol/l) 
MRC   Molecular Research Center 
mRNA  messenger RNA 
µg   microgram(s) 
µl   microlitre(s) 
µM   micromolar (µmol/l) 
ng   nanogram(s) 
nM   nanoMolar (nmol/l) 
NPL   nonparametric linkage 
OR   odds ratio 
p   probability 
p. a.  pro analysis 
PCR   polymerase chain reaction 
pH   potentia hydrogenii (hydrogen ion concentration) 
pmol   picomol 
r.t.   room temperature (ca. 20°C) 
rmax   maximum radius (centrifuge parameter) 
Rn   fluorescent emission of the normalised reporter dye 
RNA   ribonucleic acid 
rpm   rotations per minute (centrifuge parameter) 
s   second(s) 
SNP   single nucleotide polymorphism 
Taq-polymerase Thermophilus aquaticus DNA polymerase 
TaqMan®  commercial name for sequence variation detection assay, using 5’→3’ 
exonuclease activity 
TaqMan®-MGB- commercial name for sequence variation detection assay, using 5’→3’ 
exonuclease activity and 3’ minor groove binding probes 
TBE   Tris borate EDTA 
TCR   T-cell receptor 
TDT   Transmission disequilibrium test 
TE   Tris EDTA 
Tm   melting temperature 
Tris   tris-(hydroxymethyl)-aminomethane 
UC   ulcerative colitis 
UV   ultraviolet (light) 
VIC   trade name for fluorescent dye 
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Amino acid symbols 
 
A  Alanine 
C  Cysteine 
D  Aspartic acid 
E  Glutamic acid 
F  Phenylalanine 
G  Glycine 
H  Histidine 
I  Isoleucine 
K  Lysine 
L  Leucine 
M  Methionine 
N  Asparagine 
P  Proline 
Q  Glutamine 
R  Arginine 
S  Serine 
T  Threonine 
V  Valine 
W  Tryptophan 
Y  Tyrosine 
 
 
DNA base nomenclature 
 
A  Adenine 
G  Guanine 
C  Cytosine 
T  Thymine 
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1. Introduction 
 
 
 
1.1 Inflammatory bowel disease 
 
 
1.1.1 Basic concept on inflammatory disease 
 
 
1.1.1.1 Barrier organs 
 
 
Barrier organs (skin, mucosa) are of pivotal importance for the defense of the organism 
against facultative pathogens of a hostile environment. Under normal conditions, such 
barriers are maintained without any inflammation. However, for most of the barrier organs 
chronic inflammatory disorders have been described (skin: atopic dermatitis, psoriasis; 
gastrointestinal mucosa-Crohn’s disease, ulcerative colitis (inflammatory bowel disease); 
lung mucosa: asthma, sarcoidosis; oral mucosa: periodontitis.  A large overlap in clinical 
features and in molecular pathophysiology between some of the diseases is seen.  A polygenic 
susceptibility is documented for all inflammatory barrier diseases through genetic 
epidemiology (twin studies, large families) but also molecular findings (disease genes, 
linkage findings). A remarkable overlap in linkage findings suggests that some of the diseases 
may involve the same disease genes. This hypothesis could be substantiated by the analysis of 
CARD15, the first disease gene in Crohn’s disease, that plays also a role in asthma, psoriatric 
arthritis and familiar sarcoidosis (Blau syndrome), although different sequence variants are 
relevant in the latter condition. 
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1.1.1.2 Inflammation as a common response to environmental triggers 
 
 
Inflammation is one of the core reaction mechanisms of the human organism to 
environmental stimuli. While phylogenetically designed to combat infection, the same 
pathomechanisms are important in a number of autoimmune inflammatory disorders. 
Following the cloning algorithm from phenotype to genotype, these disorders share some key 
features that make a joint genomic analysis highly attractive:  
1. All diseases are epidemiologically connected to a western, industrialized lifestyle and show 
an increasing incidence in these countries. They share some of the environmental factors 
(in particular disturbances in the bacterial flora on body surfaces) that are also amenable 
to genomic approaches. 
2.   The histological appearance (mucosa associated inflammation) and cellular activation 
patterns are similar. For instance, an increased expression of inflammatory cytokines 
(TNF-α, IL-6, IL-10, IFN-γ) and activation of common signal transduction pathways 
(NFκB, JAK-STAT systems, MAP kinases) has been demonstrated for asthma, IBD, 
psoriasis, sarcoidosis and atopic dermatitis. This makes them particularly suited to a joint 
genomic analysis of disease pathophysiology. 
3. Most importantly, several genome-wide linkage studies have defined common 
chromosomal susceptibility regions that make a joint analysis (including the joint fine 
mapping, development of common makers sets, identification of candidate genes) 
scientifically highly attractive.  
4. These entities also have many clinical commonalities, including overlap of the 
phenotypes and similar treatment strategies (i.e. immunosuppression using corticosteroids 
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and other agents). A true integration of phenotypic and genotype data, therefore calls for 
an integrated, interdisciplinary phenotyping using complex clustering algorithms. 
 
1.1.1.3 Bacterial flora on body surfaces as a disease factor 
 
 
Several arguments can be made to emphasize the critical role of bacterial populations on body 
surfaces in the manifestation of the autoimmune disease investigated in this proposal. These 
arguments include: 
1. Epidemiological associations with childhood hygiene and antigen exposure exist for many 
of these disorders. The bacterial flora is clearly modified by behavioral changes 
influencing immune responses not only locally, but also systemically. Thus, many target 
organs (lung, skin and intestine) are affected by the exposure to bacteria.  
2. The intestinal immune system (over 70% of the total immune cells of the body) exists in 
close interaction with the intestinal bacteria. A well-known example is the induction and 
maintenance of tolerance to the ABO blood group antigens. 
3. Genetic animal models of intestinal inflammation demonstrate that germ-free conditions 
can completely abrogate the development of inflammatory disease. Early exposure to 
bacterial antigens attenuates later inflammatory responses to non-pathogenic bacterial 
challenges. Furthermore, it seems that sensitization to inhaled allergens is abrogated in 
animal models of asthma, if endotoxin exposure is completely absent. On the other hand, 
very high loads of microbial produces also seem to be protective against the development 
of asthma and atopic diseases. 
4. A close association between exposure to microbial matter and the development of asthma 
and atopic dermatitis has been shown in children of farmers. The more early exposure to 
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microbes the higher is expression levels of innate immunity pathogen receptors and the 
lower is the risk to develop asthma. 
Probiotic treatments have resulted in positive studies under evidence-based conditions (i.e. 
placebo controlled trials) in IBD and atopic dermatitis. 
 
1.1.2 Inflammatory bowel disease 
 
1.1.2.1 Pathogenesis and pathophysiology of IBD 
 
 
Inflammatory bowel disease (IBD) refers to a complex chronically relapsing autoimmune 
disorder of the gastrointestinal tract of unknown etiology. It is a chronic relapsing destructive 
disease, which affects the intestine and other organs (including joints, liver, pancreas, skin, 
eyes) and which results in a severe impact on the health and economic capacities of the 
adolescents affected. The disease was first described in the 1930ies and has risen in incidence 
in Europe and the US since World War II.  New data from Iceland indicate that increases in 
incidence have not stopped.  Current lifetime prevalence is estimated at 0.5-1%1 2. More 
importantly, it is thought that other unclear functional bowel disorders (IBS-irritable bowel 
syndrome, which affects up to 30% of the population > 40 years) can to a certain extent be 
attributed to abortive forms of IBD (i.e. resulting in disturbed bowel function but not the 
characteristic ulcerations). IBD is also considered as a prototype, which will help in the 
understanding of other chronic inflammatory disorders (e.g. rheumatoid arthritis) where the 
phenotype is less clear and the disease organ is less accessible.  It has been classified into 
Crohn’s disease (CD) and ulcerative colitis (UC) based on clinical, radiologic, endoscopic 
and pathological criteria 3 (Table 1.1.2.1). IBD is characterized by a chronic relapsing activity 
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with problem-free phases (“remission”) intervening with phases of inflammatory activity 
(“flair”). The clinical features include abdominal pain, (bloody) diarrhea and complications 
such as groth retardation in children, anemia, toxic megacolon and stenosis and fistulae (in 
Crohn disease). While some patients develop a chronically active disease in which 
inflammatory activity of different degrees is always present, others come to a complete 
clinical remission between active episodes.  The immunological causes responsible for the 
different types of disease behavior are unclear and the triggers for the development of 
relapses are unknown. Extra-intestinal manifestations can also occur, including skin ulcers, 
arthritis, and bile-duct inflammation, the last especially in UC. Both UC and CD are 
characterized by mucosal ulceration. In CD, ulcers penetrate into the gut wall, and fistulous 
tracts may develop between loops of bowel or to the skin. IBD is a multifactorial disease 
caused by the interplay of genetic, environmental and immunological factors 4.  Multiple 
studies have suggested that first-degree relatives of an affected patient have a risk of 
inflammatory bowel disease that is 4 to 20 times as high as that among the background 
population; the absolute risk of inflammatory bowel disease is approximately 7 percent 
among first-degree family members 5 6. Epidemiological and genetic linkage studies in IBD 
provide a thorough proof for a genetic background 7 8, and a first disease gene (NOD2 or 
CARD15) has been identified for CD 9 10 11. The lifestyle of an industrialized society is 
important for the penetrance of the genetic factors 12 (Figure 1.1.2.1). 
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Table 1.1.2.1 Differences between Crohn’s disease and Ulcerative Colitis 
Disease Ulcerative Colitis Crohn’s disease 
Symptoms Diarrhea Diarrhea 
 Bloody Diarrhea Rectal bleeding 
 Pus or mucus in the stool Wight loss 
 Severe abdominal cramps Pain & tenderness in abdomen, 
especially the lower right side 
 Nausea Low-grade fever 
 Frequent fever Sometimes constipation because of 
a blockage 
  Slowed growth and delayed sexual 
development in some childhood 
cases 
Parts of digestive system affected Only the top layers of the walls of 
the colon or rectum (most often in 
the lower part of the colon and 
rectum) 
Deep in the lining of the walls of 
the colon and/or small intestine. 
Any part of the digestive tract from 
mouth to anus 
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Fig 1.1.2.1 Possible causes of inflammatory bowel disease 
 
 
 
 
 
 
 
 
 
 
 
 
The disorder of Crohn’s disease is characterized by transmural inflammation that could affect 
any part of the gastrointestinal tract, and the disease relapses and remits throughout its course. 
In CD inflammation can arise anywhere in the digestive tract from the mouth to the anus. 
Aggregates of immune cells consisting of T cells, monocytes and macrophages in the bowel 
wall can be observed in half of the cases. The structure of the mucosa is distorted and shows 
progressive atrophy. A simple cause and effect relation probably does not account for most 
cases of Crohn’s disease. The pathogenesis of the disease is complex and consists of three 
interacting elements: genetic susceptibility factors, priming by the enteric microflora, and 
immune-mediated tissue injury 13 14 15.  
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Ulcerative colitis is a worldwide, chronic, idiopathic inflammatory disease of the rectal and 
colonic mucosa. Inflammation in UC starts in the rectum and extends proximally up the 
bowel. The damage of the mucosa is continuous from the rectum to the proximal colon 
without evidence of skip lesions. The inflammation is located predominantly within the 
lamina propria of the mucosa. Scattered crypt abscesses with ulceration and islands of 
regenerating mucosa forming pseudopolyps are observed. A severe course of UC is the 
formation of a toxic megacolon, a sudden cessation of bowel function leading to toxic 
dilatation and eventual perforation of the bowel. As only the inner lining of the intestine is 
affected in UC, nearby organs are not affected by the formation of fistulae. Both CD and UC 
can lead to numerous extra-gastrointestinal inflammatory manifestations in the liver, eyes, 
skin and joints 3.The gut lamina propria is constantly exposed to antigens and pathogens 
coming along with the nutrition. After a primary inflammatory process microbes and 
microbial products may infiltrate the submucosa or lamina propria, resulting in a reinforced 
inflammation leading to an increased mucosal damage 16. 
 
When the state of inflammation shifts from the physiologic to the pathogenic state, the pro-
and anti-inflammatory cytokines become imbalanced 17 18. In CD, a predominant TH1 
response with elevated levels of IL-2 and IFN was observed in studies 19 20. In UC, humoral 
immunity with an increased level of IL-5 and IL-10 seems to predominate, but evidence for a 
classical TH2 situation is scarce 4 21. In both CD and UC, activated macrophages participate 
in the mucosal immune response, e.g. by producing pro-inflammatory cytokines such as TNF-
a, IL-1 and the chemokine IL-8 22 23 24. It has been suggested that TNF-α plays a central role 
in the pathogenesis of CD and is likely to be at the apex of the inflammatory cascade 18 20 22 
25. In almost half of UC affected individuals and in a small group of CD cases, a perinuclear 
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antineutrophil cytoplasmic antibody (p-ANCA) can be detected. It seems to be more 
prevalent in more aggressive UC. P-ANCA reactivity is suggested to derive from the 
recognition of heterogeneous neutrophil-associated antigens 26 . A sub group of the antibody, 
called atypical p-ANCA, recognizes a 50 kD myeloid-specific nuclear envelope protein that 
can be detected in UC affected carriers of the antibodies 27. 
 
1.1.2.2 Genetic background of inflammatory bowel disease 
 
 
Epidemiological and family studies have provided overwhelming evidence that genetic 
factors have an important role in determining susceptibility to IBD 28. Systematic 
investigations of affected families show relative sibling risks of 15-35 for Crohn’s disease 29 
30 and 6-9 for UC 6 31 32. This and an increased concordance of the IBD phenotype in 
monozygotic twins 5 33 clearly show a genetic cause of the disease. In 25% of multiply 
affected families cases of CD and UC are present 34. Several susceptibility loci were 
identified: IBD1 on chromosome 16 35 36; IBD2 on chromosome 1235; IBD3 on chromosome 
6 37 38; IBD4 on chromosome 1439 40; IBD5 on chromosome 541 38; chromosome 1 42; 
chromosome 1938 and as well on chromosome X 43 (table 1.1.2.2). Most subsequent studies 
supported a polygenic mode of inheritance, and it has since become clear that environmental 
factors represent significant risk modifiers 44. 
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Table 1.1.2.2 Gene map locus for inflammatory bowel disease 
Locus name Region 
IBD1 16q12 
IBD2 12q13 
IBD3 6p 
IBD4 14q11-q12 
IBD5 5q31 
IBD6 19p13 
IBD7 1p36 
IBD8 16p 
 
Within the linkage region on chromosome 16 (IBD1) a first disease gene CARD15 (or 
NOD2) has been identified. Variants of the NOD2 gene (C14772T (R702W) in exon 4, 
G25386C (G908R) in exon 8 and 32629insC (1007insC)) are highly associated with CD 9 10 
11, but cannot account for all cases. Among other functions, NOD2 may be involved in NF-kB 
signalling 16. Besides this first gene, the multiple linkage regions and segregation models 
indicate that more than one risk allele is involved in the pathogenesis of IBD 45 46. A stronger 
association exists between genes of the human leucocytes antigen region and UC 47. A 
positive association with DR2 and the rare alleles DRB1*0103 and DRB1*12 and negative 
association with DR4 and DRw6 have been reported 4 47. 
 
1.1.2.3 Linkage region on chromosome 12 
 
 
A candidate region on chromosome 12 (the IBD2 locus [MIM 601458]) has been reported for 
both CD and UC 8,35,48-51, but some studies claimed to exclude this region 52-54. Miles Parkes 
et al 55 demonstrated that IBD2 appears to make a major contribution to UC susceptibility but 
to have only a relatively minor effect with regard to CD. A number of plausible candidate 
genes have been investigated with negative results, including the beta 7 integrin gene 56 and 
the STAT-6 gene 57. 
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1.1.2.4 Linkage region on Chromosome 7 
 
 
Suggestive evidence for linkage at chromosome 7q near D7S669 was initially reported in a 
European cohort consisting of 186 affected sibling pairs from 160 families 35. Several 
candidate genes on this region had been evaluated 58-60. 
 
1.2 Globlet cell function 
 
 
 
The epithelial mucosal layer is a very important barrier that can protect the animal body from 
dryness, harmful exogenous substances and pathogens. Mucus is secreted by the epithelial 
surfaces throughout the gastrointestinal tract from the stomach to the colon. It forms a gel 
adherent to the surface that provides a protective barrier between the epithelium and the 
exterior environment. Mucus serves many functions, including protection against shear stress 
and chemical damage. The mucus layer on top of the intestinal epithelium is the barrier 
between the host's internal milieu and gut bacteria 61. Mucins are the primary component of 
the mucus. They are glycoproteins that are deemed to mediate many interactions between 
these cells and their milieu 62. Mucins and other components of mucus are secreted from the 
apical surface of specialized columnar epithelial cells referred to as goblet cells 63.  
 
Goblet cells are distributed among other cells in the epithelium of many organs, especially in 
the intestinal and respiratory tracts. Goblet cells reside throughout the length of the small and 
large intestine and are responsible for the production and maintenance of the protective 
mucus blanket by synthesizing and secreting mucins. Goblet cells have a characteristic 
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morphology, based on membrane-bound secretory granules, which contain mucus 64.  
 
The goblet cells' function is the secretion of mucins and other products, including protease 
resistant peptides--like the trefoil peptide family, which protects epithelium from injury and 
promotes repair through restitution of epithelial cells 65. Secretion of mucus occurs by 
exocytosis of secretory granules 66. After the secretion, mucins have the ability to form a 
viscous gel, producing a protective scaffold overlaying epithelial surfaces.  
 
Epithelial cell differentiation in mucosal tissues has been studied to some detail in the 
gastrointestinal tract endoderm and the bronchial airways 67 68. The small intestinal epithelium 
consists of four principal cell types: enterocytes, goblet, enteroendocrine and Paneth cells 69.  
 
When the mucus production is altered, it can cause various diseases. As in asthma, chronic 
obstructive pulmonary disease (COPD), and cystic fibrosis, the mucus productions are 
increased, whereas in dry eye syndrome, gastric disease, peptic ulcer, and inflammatory 
bowel disease are decreased. Altered mucus production is also described in malignancies like 
colorectal cancer 70 71 72. 
 
 
1.3 Mouse model 
 
 
 
A mouse phenotype with diarrhea and goblet cell dysfunction caused by anterior gradient 
protein 2 dysfunction was reported (European patent WO2004056858). In the patent, the 
authors performed a genome wide screen for mutations influencing epithelial functions in 
mice, e.g. nutrient absorption by intestinal mucosa. The responsible mutation was identified 
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by positional cloning and shown to result in an amino acid exchange within "anterior gradient 
2" (AGR2) by the Mouse Genome Informatics database. This gene is expressed in murine 
intestinal tissues, specifically in intestinal goblet cells 73. The human homologous gene is 
“Anterior gradient 2 homolog” (AGR2). Comparing to the mouse AGR2 gene, it encodes a 
protein with 91% amino acid identity.  
 
They analyzed the RNA expression profile of the mouse Agr2 gene and the human AGR2 
gene. The phenotype observed in the mouse model demonstrates that AGR2 function is 
required for normal goblet cell function in a mammalian model organism. In the patent, they 
provide mutated AGR2 nucleic acids and polypeptides having modified sequences compared 
to the wild type sequences. In a specific embodiment, an AGR2 mutein carries an amino acid 
substitution at residue 137. The amino acid substitution is the substitution of a codon 
encoding valine at position 137 to a codon encoding a non-valine (glutamic acid) substitution. 
They use gene knockout method to produce a mouse model that only contains mutated AGR2 
gene.  
  
The goblet cells referred to in this study are specialized with respect to mucus secretion via 
granules, in particular in the gastrointestinal tract (GI) (examples in this regard are goblet 
cells of the esophagus, of the stomach surface, of the pyloric glands, and of the intestinal 
epithelium), or in the respiratory tract (examples in this regard are goblet cells of the nose 
epithelium, of the trachea, of the bronchius, and of the submucosal glands of the trachea).  
 
The patent demonstrates that AGR2 is required for normal goblet cell function and that 
mutating this gene and its gene product may result in goblet cell dysfunction and 
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corresponding physiological and medical disorders of the affected animal. The results of this 
experiment indicate that human AGR2 mRNA is strongly expressed in stomach, duodenum, 
ileocecum, ileum, descending colon, transverse colon, caecum, and rectum. Weaker 
expression is detected in lung, cervix, and prostate. AGR2 is a secreted protein released from 
cultured colon cancer cells. Western blot analysis predicted that any mutation in the AGR2 
gene resulting in abnormal AGR2 peptide expression levels in an individual will interfere with 
the peptide's normal biological function, including in a manner analogous to that observed in 
the present invention. Mutations leading to abnormal AGR2 peptide expression levels might 
affect any aspect of gene expression, e.g. DNA transcription, mRNA transport and 
processing, mRNA translation or AGR2 peptide half-life itself.  
 
The patent demonstrates for the first time that AGR2 is required for normal goblet cell 
function, in particular mucin secretion.  
 
 
1.4 AGR2 function 
 
 
 
The cement gland is an ectodermal organ in the head of frog embryos, lying anterior to any 
neural tissue. The cement gland was induced by the dorsal mesoderm. Mesoderm with the 
highest cement gland-inducing potential lay posterior to the ectoderm fated to form this 
organ, indicating that its induction occurred at a distance from the inducer source. Cement 
gland induction first occurred during early gastrulation.  
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The functional analysis of a protein homologue to human AGR2 has been performed in 
Xenopus laevis. The overexpression of XAG-2 induces both cement gland differentiation and 
expression of anterior neural marker genes in the absence of mesoderm formation 74. The 
Xenopus protein exhibits 59% amino acid identity to mouse AGR2 protein, and exhibit 60% 
amino acid identity to human AGR2 (Fig 1.4a and Fig 1.4b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     F
       
 ig 1.4a  Nucleotide sequences of AGR2 cDNA and alignment with other species using   
             clustal X 75. 
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   Fig 1.4b Amino acid sequences of AGR2 cDNA and alignment with other species using    
               clustal X 75. 
 
Human AGR2 (also termed BCMP7 and XAG-1) is a known protein. There are several 
patents which study the elements (such as growth factor, PRO 1030, EST sequence) whose 
response to AGR2 can cause colon cancer (WO 98/07749, WO 99/55858, WO 00/53755). 
Human AGR2 mRNA was shown to be expressed in trachea, lung, stomach, colon, prostate 
and small intestine 76.  
 
  
1.5 Disease gene detection in complex disease 
 
1.5.1 Linkage analysis 
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Epidemiological evidence shows that many diseases have genetic background and it is 
important to identify the genes that carry the disease causing mutation. There is more than 
20,000 genes are known and the amount of genes that is estimated for the human genome is 
about 30,000 to 50,000 genes 77 78 79. The purpose of genome-wide linkage analysis is to 
reduce the area of the genome in which such a gene could be situated. In complex disease, 
linkage analysis is performed to detect a co-segregation between a marker and a putative 
disease locus. In linkage analysis, co-segregation of two or more genes is examined in a 
family unit to determine if they segregate independently according to Mendel’s laws or if 
they do not segregate independently because of their close physical proximity. If the two 
homologous chromosomes segregate independently, alleles at loci on the same chromosome 
should co-segregate at a rate (θ) which is somehow related to the distance between them on 
the chromosome. This rate is the probability of a recombination event occurring between the 
two loci. Multiple recombination events can occur on the same chromosome. Two loci are 
said to be genetically linked when θ ≤ 0.5, and the phenomenon describing this occurrence is 
genetic linkage. The object of linkage analysis is to estimate θ and to test if θ ≤ 0.5. 
Recombination between each of the genetic markers and the disease "marker" is determined 
based on the frequency each allele was observed. The maximum likelihood that the observed 
data are caused by a determined recombinant fraction is tested. The likelihood for each value 
of the recombinant fraction between pairs of markers is compared and thereby the odds ratio 
and the logarithm of the odds ratio (LOD score) are determined. The LOD score indicates the 
likelihood of linkage 80. The most probable position of the disease "marker" is between those 
2 genetic markers where the smallest recombination frequency is measured, indicating the 
strongest linkage and the shortest genetic distance. The maximum likelihood estimate (MLE) 
is the value that gives rise to the largest value of the likelihood (or LOD score) 81. The MLE 
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is highly efficient, in the sense of the precision obtained using a given set of data. With 
increasing sample size it will converge closer to the true value.   
 
The usual likelihood-based approaches for genetic linkage analysis require that a correct 
model be specified for the relationship between an individual’s genotype and the 
corresponding chance of displaying a disease or other trait phenotype. The non-parametric 
linkage (NPL) analysis methods, like the affected-sib-pair (ASP) method, do not require that 
the genetic model explaining disease inheritance be explicitly specified. The NPL is usually 
measured in the analysis of a qualitative trait. 
 
Multipoint linkage analysis is the usual method where several markers at the same time are 
used to map the disease locus. The analysis of the polymorphic markers is performed in 
affected sibling pairs (ASP). They share the disease allele through identity by descent (ibd). 
With the determination of the allele status at the polymorphic marker, recombination can be 
detected between the marker and the disease allele. The closer the disease allele is linked to 
the marker, the less recombination can be expected and the higher the LOD score is. Taking 
the possibility of false positive results in account, a critical value of > 3.6 for the LOD score 
were suggested 82. However, LOD scores depend on the density and information content of 
the marker, the size of the ASP population and preciseness of the disease phenotype 83. 
 
1.5.2 Association mapping analysis 
 
 
Linkage analysis locates the approximate position of genes. The association design takes a 
known gene and tests whether individual differences in the gene are statistically associated 
with a phenotype. A linkage region can be several Mb long and contain several hundred 
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genes. For association analysis, the density of markers is increased (3 to 50 kb) and usually 
diallelic single nucleotide polymorphisms (SNPs) are employed as markers. Association 
studies can be family or population based, resulting in two different analysis methods: the 
transmission disequilibrium test (TDT) for family based studies 84 and the case control 
analysis for population-based studies. 
 
In a population based study with the case control set-up, the Pearson's χ2 statistic (or any 
other appropriate χ2 statistic) is calculated. P value calculated from association studies must 
be corrected for the number of loci analyzed and the number of alleles at each loci. Number 
of samples required depends on the number of markers tested, the population frequency of the 
susceptibility allele and the relative risk of the susceptibility allele 85. 
 
The transmission disequilibrium test (TDT) was developed by Spielman 86, as a method to 
test for linkage in the presence of association. The original version of the TDT used a 
McNemar chi-square to assess preferential transmission of allele A to affected offspring from 
AB heterozygote parents. If allele A is transmitted significantly more than half of the time, it 
can be concluded that the AB marker locus is linked to a disease predisposition locus, and 
that allele A is positively associated with an allele that increases disease susceptibility.  
Different methods to evaluate the transmission to the affected offspring have been developed. 
Either transmitted alleles are compared direct to untransmitted alleles or the difference to the 
number of alleles expected to be transmitted according to HWE is analyzed 87 88 89. TDT 
association studies are considered to be more sensitive (having greater power) than linkage 
methods to detect genes with small to moderate effects on disease 89. The TDT is only a valid 
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test of association if one affected offspring per family is used. It is always valid as a test of 
linkage, but its power is low when association is weak or absent.  
 
1.5.3 Candidate gene analysis 
 
 
The systematic positional cloning approach outlined above is extremely time and cost 
consuming. The direct evaluation of functional candidate genes is one possibility to directly 
identify the causative molecular variants. The chances for success of this process depend 
critically on the pathophysiology-based choice of the candidate gene. In addition, expression 
studies together with the chromosomal localization of a transcript can be used to define 
“positional candidate genes”. Differentially regulated transcripts identified through 
expression profiling are another important contributor to the selection of candidate genes.  
In fact, once disease related disequilibrium is identified in a genomic region, the identified 
transcripts have to be also tested in a candidate gene approach. Study design is a critical 
factor as case-control studies are susceptible to false positive findings due to population 
stratification. Performing case-control studies, special care needs to be taken in order to 
ensure a genetic matching of study cohorts. A robust alternative is the use of family based 
association designs like the haplotype relative risk (HRR) or transmission disequilibrium test 
(TDT). Furthermore, the replication of results in different, independent and large cohorts is 
thought to be critical to assess the true value of association results. The choice of the 
candidates to be studied is driven by the prevailing immunological theories and restricted to 
known genes. However, in recent years the knowledge about disease pathways has increased 
dramatically and genetic studies of disease pathways, e.g. in the innate and adaptive immune 
system, start to replace single gene association studies. Thus, gene-gene interactions are 
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increasingly taken into account in a more systematic approach of extended haplotype studies. 
Furthermore, gene expression profiling and comparative studies between murine and human 
disease models add to the potentials of candidate gene approaches. Carefully conducted 
candidate gene studies remain a powerful tool, also in view of the methodological problems 
outlined for the positional cloning method. In many situations, like for instance the search for 
disease modifying genes or in pharmacogenetics, case-control candidate gene studies will 
remain the only viable instrument. In general variants in the candidate genes will either be 
taken from the public SNP databases or will be generated in-house by re-sequencing of 
affected individuals.  
 
The analysis of candidate genes is a key step in strategies for disease gene identification. In 
simple diseases, linkage and positional cloning can be used. But for complex diseases, these 
methods have not been successful. The failure is the result of three main features of complex 
disease: (1) the diseases vary in severity of symptoms and age of onset; (2) they can vary in 
their aetiological mechanisms; (3) they are more likely to be caused by several genes, each 
with a small overall contribution and relative risk. Candidate-gene studies focus on genes that 
are selected because of a priori hypotheses about their aetiological role in disease. 
Furthermore, a candidate-gene study is usually conducted in a population-based sample of 
affected and unaffected individuals. Therefore, candidate-gene study takes advantage of both 
the increased statistical efficiency of association analysis of complex diseases and the 
biological understanding of the phenotype, tissues, genes and proteins that are likely to be 
involved in the disease.  
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The selection of candidate genes has many parallels with identifying and ranking risk factors 
in an epidemiological study. Candidate genes may be identified based on functional 
information about the disease and/or on genetic map information obtained by linkage or 
linkage disequilibrium. Candidate genes are genes of known biological action involved with 
the development or physiology of the trait biological candidates. They may be structural 
genes or genes in a regulatory or biochemical pathway affecting trait expression. Some genes 
may be excellent candidate genes based on similar phenotypes seen in other species. 
Expression studies might provide important information about the tissues and cells that are 
involved in the disease 90 91 92.  The chosen number of candidate genes and variants is 
influenced by many considerations 93. 
 
The criticisms of candidate-gene approaches are rooted in a fundamental challenge to the 
study of the genetics of complex diseases. Some of the candidate-genes cannot be replicated 
in different populations. Lack of replication may be caused by different reasons. First, the 
finding of association studies often cannot be replicated 94. Second, discrepant findings are 
often due to the variations in study design. Third, the selections of polymorphisms are not 
likely to be causal. Most candidate genes considered only a small number of candidate genes 
and variants. 
 
A polymorphism is a variation in DNA sequence that has an allele frequency of at least 1% in 
a population. Most of the DNA sequence variation in the human genome is in the form of 
single nucleotide polymorphism (SNP) 95. The statistical power to detect a significant 
association depends on the size of the association and the frequency of the allele of interest 
85,93,96. The SNP with very low allele frequencies would need to have very large relative risks 
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associated with them to be detected in a candidate gene. SNPs with frequencies of at least 5% 
are generally more likely to be useful in a candidate-gene study 97. Another important 
consideration in selecting SNPs is whether there is significant linkage disequilibrium in the 
candidate gene in the study population. The use of rigorous epidemiological principles for the 
choice and analysis of candidate genes and SNPs in disease studies is one tool that might 
improve the chance of a successful outcome. 
 
1.5.4 Pathway-mapping to establish the link between genetic variants and 
pathophysiology 
 
 
Positional cloning results and positive candidate gene studies lead to the identification of 
sequence variants that are strongly associated with disease and therefore suggested as 
possible causative factors.  However, the proof of a causative relationship requires functional 
studies detailing disease mechanisms.  Likewise, only functional studies can explore the 
pathways originating from disease genes and their uplink into disease pathophysiology.  Most 
of the genes identified lack a full gene structure or a functional annotation, respectively. 
Detailed functional analysis and evaluation of biological relevance in the context of barrier 
function and chronic inflammation requires a systematic approach using advanced molecular 
and bioinformatics tools.  
 
The molecular tools for pathway mapping have to address a wide range of mechanisms 
observed in disease genes described or under study in this network (from clear structural 
changes due to amino-acid exchanges or truncating mutations (e.g. an insertion mutation 
causing a frame shift as demonstrated for NOD/CARD15-SNP13) to more complex effects 
including alterations in mRNA stability, promoter activity or regulation of alternative splicing 
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(e.g. IL-13, STAT6). The mappping of pathways originating from disease genes will 
ultimately reveal new therapeutic targets in the uplink to more generic mechanisms in disease 
pathophysiology. For this purpose explorative techniques to systematically analyze 
expression regulation (i.e. microarrays, real time PCR) and to detect protein-protein 
interactions are used. 
 
Pathway mapping integrates functional genomical approaches generated to assign a cellular 
function to a molecular variant ultimately leading to a disease phenotype. The connections 
have been established to gain access to key technologies including systematic splicing and 
allelic expression analysis, RNAi, high-throughput yeast two hybrid, proteomics (2DGE, 
MALDI-TOF), HTS-reporter gene assays, ChIP on Chip and standardized generation of 
stably transfected cell lines will be used to address key questions that evolve from the 
identified disease genes. As an important element, pathway-mapping needs to combine a 
series of highly standardized technological platforms and resources that provide complex 
material like tissue from animal models and patients available in a systematic fashion. 
 
1.6 Aims of this study 
 
 
1. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. 
2. Identification of susceptibility marker for inflammatory bowel disease on chromosome 
12q linkage region. 
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2. Materials and methods 
 
 
 
2.1 Materials 
 
 
Table 2.1 Materials part 1 
Material Manufacturer / Supplier 
100 bp DNA ladder Invitrogen; Karlsruhe, Germany 
2.2 ml storage plate (96 well) ABgene, Epsom, UK 
384 deep well storage plate ABgene, Epsom, UK 
Agarose Eurogentec; Köln, Germany 
AmpliTaqⓇ DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
AmpliTaqⓇ Gold DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
BacillolⓇ Bode Chemie; Hamburg, Germany 
BigDye Terminator Ready reaction kit Applied Biosystems; Weiterstadt, Germany 
Bromophenol blue Sigma; München, Germany 
Cell culture flasks (250 ml; canted neck) BD Biosciences; Heidelberg, Germany 
Cryotubes (2ml) Greiner Bio-One GmbH; Frickenhausen, Germany 
DNAzolⓇ Molecular Research Center, inc. Cincinatti, 
Ohio, USA 
dNTP set (100mM solutions @ 100µM 
each ) 
Amersham Biosciences; Freiburg, Germany 
Easy peel heat seal foil ABgene, Epsom, UK 
EDTA Sigma; München, Germany 
EDTA blood vial 9 ml Sarstedt; Nümbrecht, Germany 
Ethanol p. a. Merck; Darmstadt, Germany 
Ethanol technical Bundesmonopol für Branntwein (BfB); 
Offenbach, Germany 
Ethidium bromide solution (10mg/ml) Invitrogen; Karlsruhe, Germany 
ExoI (Exonuclease I) Amersham Biosciences; Freiburg, Germany 
GeneAmp PCR buffer system (10x buffer 
w/o MgCl2; 25mM MgCl2 solution) 
Applied Biosystems; Weiterstadt, Germany 
Glycerol Sigma; München, Germany 
Invisorb Blood Giga Kit Invitek, Berlin, Germany 
isopropanol Merck; Darmstadt, Germany 
MgCl2 Merck; Darmstadt, Germany 
MicroAmpⓇ optical 96 well reaction plate Applied Biosystems; Weiterstadt, Germany 
MicroAmpⓇ single strips Applied Biosystems; Weiterstadt, Germany 
MicroAmpⓇ single tubes Applied Biosystems; Weiterstadt, Germany 
Microtiter 384 well plates Sarstedt; Nürnberg, Germany 
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Table 2.1 Materials part 2 
Material Manufacturer/Supplier, Country 
Microtiter 384 well plates Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Microtiter 96 well plates Sarstedt; Nürnberg, Germany 
Microtiter 96 well plates Costar Corning Incorporated; Cambridge, 
MA, USA 
Microtiter plates, 96-well, round bottom, with lid Sarstedt; Nümbrecht, Germany 
Microtiter strips (Nunc-Immuno 
MaxisorpTM , 8-well, flat bottom) with 96-well 
frame 
Nunc; Wiesbaden, Germany 
Multiscreen column loader Amersham Biosciences; Freiburg, Germany 
PEQLAB DNA isolation system PEQLAB Biotechnology GmbH; Erlangen, 
Germany 
PicoGreen Molecular Probes Europe BV, Leiden, The Netherlands 
Pipette (serological, sterile with filter 5 / 
10 / 25 ml) 
Sarstedt; Nümbrecht, Germany 
Pipette tips with filter (10 / 200 / 1,000 µl) Sarstedt; Nürnberg, Germany 
protein-kinase K Invitek, Berlin, Germany 
proteinase K Molecular Research Center, inc. Cincinatti, 
Ohio, USA 
saccharose Merck; Darmstadt, Germany 
SAP shrimp alkaline phosphatase Amersham Biosciences; Freiburg, Germany 
Sephadex powder (G50 superfine) Amersham Biosciences; Freiburg, Germany 
Sephadex spin column plates MAHVN 
4550 
Amersham Biosciences; Freiburg, Germany 
SmartLadder DNA marker Eurogentec; Köln, Germany 
TAE Buffer 25x ready pack Amresco; Solon, OH, USA 
TaqMan ® Universal PCR Master Mix Applied Biosystems; Weiterstadt, Germany 
TBE buffer 10x ready pack Amresco; Solon, OH, USA 
TEMED Sigma; München, Germany 
Tris Merck; Darmstadt, Germany 
Triton-X Sigma; München, Germany 
Trypsin / EDTA (0.25% / 1 mM) Invitrogen/Gibco; Karlsruhe, Germany 
Tubes (0.5 / 1.5 / 2.0 mL) Eppendorf; Köln, Germany 
Tubes (0.5, 1.5, 2 mL) Eppendorf; Köln, Germany 
Tubes, flat bottom (60 mL) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (15 mL) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (50 mL) BD Biosciences; Heidelberg, Germany 
Xylene Cyanol FF Sigma; München, Germany 
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2.2 Electronic database 
Applied Biosystems   http://www.appliedbiosystems.com/
BLAST     http://www.ncbi.nlm.nih.gov/BLAST/
Celera Discovery Systems http://www.celera.com/
dbSNP     http://www.ncbi.nlm.nih.gov/SNP/index.html
Gene Cards    http://www.genecards.org/
Locus Link    http://www.ncbi.nlm.nih.gov/LocusLink/
MAP viewer    http://www.ncbi.nlm.nih.gov/mapview/
NCBI     http://www.ncbi.nlm.nih.gov/
PubMed     http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
UCSC Genome Browser   http://genome.ucsc.edu/
Repeat Masker   http://repeatmasker.genome.washington.edu/cgi-bin/RepeatMasker
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2.3 Participants and study design 
 
2.3.1 Investigated patient sample of AGR gene 
 
 
In this study, two groups of participants were investigated. The first group included a sample 
of 383 cases from families and 565 trios with IBD (631 with CD, 317 with UC) and 537 
unrelated healthy control individuals of German extraction. The second group consisted of 
604 cases from families and 91 trios (384 with CD and 311 with UC) and 360 unrelated 
healthy control individuals from the United Kingdom. For each affected individual, the 
diagnosis of either CD or UC was confirmed by standard diagnostic criteria 3 98. 
Ascertainment criteria were determined prior to the initiation of patient collection. German 
patients and their family members were recruited at the 1st Department of Medicine at the 
Hospital Schleswig-Holstein, Campus Kiel (Kiel, Germany), the Charité University Hospital 
(Berlin, Germany) and other collection centers in Germany. The control individuals were 
collected through the Department of Transfusion Medicine at the University Hospital 
Schleswig-Holstein and through the POPGEN population project (www.popgen.de). UK 
families were sampled through the King's College School of Medicine, Guy's Hospital, and 
the St. Mark's Hospital London (UK). The cohorts have been used in a number of previous 
studies and the clinical and ethical issues of the recruitment process were reviewed as part of 
these publications 99 50 11 46. An overview of the investigated sample is given in table 2.3.1.  
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Table 2.3.1: Overview of the investigated cohort: Non-overlapping categories are given. 
Single cases were randomly selected from IBD families. 
Population Cases Controls 
 CD UC  
 Trios Cases 
from 
families 
Total 
independent 
cases 
Trios Cases 
from 
families 
Total 
independent 
cases 
 
Germany 377 254 631 188 129 317 537 
UK 56 328 384 35 276 311 360 
 
 
 
2.3.2 Association study population on chromosome 12 
 
 
In this study, one group of participants was investigated. This group included a sample of 
776 trios with IBD (484 with CD, 292 with UC) and 360 unrelated healthy control 
individuals of German extraction. For each affected individual, the diagnosis of either CD 
or UC was confirmed by standard diagnostic criteria 3 98. Ascertainment criteria were 
determined prior to the initiation of patient collection. German patients and their family 
members were recruited at the 1st Department of Medicine at the Hospital Schleswig-
Holstein, Campus Kiel (Kiel, Germany), the Charité University Hospital (Berlin, 
Germany) and other collection centers in Germany. The control individuals were 
collected through the Department of Transfusion Medicine at the University Hospital 
Schleswig-Holstein and through the POPGEN population project (www.popgen.de). The 
cohorts have been used in a number of previous studies and the clinical and ethical issues 
of the recruitment process were reviewed as part of these publications 99 50 11 46.  
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2.3.3 Sequencing samples 
 
 
For the sequencing of genomic DNA, the DNA was extracted from peripheral blood 
lymphocytes as described in the DNA isolation section and arrayed into a 96 well plate 
format. Each well contained 5 ng of liquid DNA. The samples consisted of unrelated 
German individuals affected with IBD from the population sample for association studies. 
For the mutation detection of the AGR gene, one IBD population sample, which was 
composed of 47 unrelated German individuals (24 with CD, 23 with UC) and one empty 
control, was used for sequencing. The samples were applied to a 96 well plate in 
duplicate. Another sequencing population, which included 47 UC patients and one 
control, was used for mutation detection of candidate genes on chromosome 12. 
 
2.4 Handling of samples 
 
 
The local ethics committees at participating institutions recruited patients. IBD patients 
were chosen according to standard diagnostic criteria 3 98. Patient contact was initiated 
through the general practitioner or a medical center and informed written consent was 
obtained from all participants. Two tubes of 9 ml EDTA blood were collected from the 
patients. Additionally, a questionnaire inquiring about disease circumstances, other 
diseases, and environmental factors was received from every patient and their family 
members. All material was sent back by regular post 37 50. The blood was immediately 
frozen at –80°C and stored at this temperature until the preparation of the DNA. Samples 
that were collected by collaborators were either sent as frozen EDTA blood or as 
extracted DNA. Informed written consent was obtained as well from the non-IBD sample 
populations. 
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2.4.1 DNA isolation 
 
 
DNA isolation from EDTA-full blood by guanidine-detergent lysis with DNAzolⓇ was 
performed either from fresh or from frozen samples, stored at -80°C 100. About 9 ml blood 
was used. Frozen samples were thawed at room temperature immediately before 
preparation by gently inverting the blood vial occasionally. All of the following 
procedures were conducted on ice. Eighteen ml of MRC buffer (Molecular Research 
Center; 320 mM saccharose, 5 mM MgCl2, 1 % Triton-X, 1 mM Tris at pH 7.5) was 
transferred with the blood sample to sterile 50 ml tubes and admixed and incubated for 10 
minutes. During this step the red blood cells were destroyed and protein particles were 
separated from intact leukocytes. The samples were centrifuged for 10 min at 10000 xg at 
4°C. The supernatant was discarded and the pellet rinsed with 5 ml MRC buffer, which 
was discarded directly afterwards. The pellet was resuspended in 9 ml MRC buffer and 
then MRG buffer was added to a total volume of 18 ml. Incubation and centrifugation 
were repeated as described. The pellet was resuspended in 5 ml of DNAzolⓇ and 
incubated at room temperature for 15 min until the solution was transparent. In this step 
the leukocytes were destroyed and the DNA was set free from the nuclei. Proteinase K 
(stable for 4 weeks at -20°C, 100 µg/ml final concentration) was added and the solution 
was incubated at room temperature for up to 12 h for enzymatic digestion of proteins. 2.5 
ml ice-cold absolute ethanol (0.5 vol. per 1 vol. DNAzolⓇ) was added and gently mixed 
by inverting the tube. A small thread of DNA precipitate floating in the liquid was 
transferred into a labelled DNAse free 1.5 ml tube. The precipitate was then washed with 
96% and then briefly with 70% ethanol. Supernatants from each washing step were 
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discarded. The precipitate containing the DNA was then dried at room temperature for 
several hours (overnight) and then reconstituted in 500 – 1000 µl Tris EDTA buffer (TE), 
depending on the approximate yield of DNA. To maximize solubilization of the DNA 
pellet, the solution was incubated 24 hours at room temperature and stored at 4°C until 
further use. 
 
Invisorb Blood Giga Kit (Invitek, Berlin, Germany) was also used for preparing DNA. 
Frozen blood samples were thawed in cold water, while gently inverting the blood vial 
occasionally. Thawed blood samples were transferred to labeled sterile 50 ml tubes 
previously filled with 30 ml of "Buffer 1" (4°C), shaken and incubated for 10 min at room 
temperature. During this step the red blood cells were destroyed while the leukocytes 
stayed intact. The samples were centrifuged for 3 min at 6000 xg and the supernatant 
discarded. Another 20 ml of "Buffer 1" was added to the vial, mixed until the pellet was 
dissolved, and then centrifuged as above. This step was repeated until the pellet was 
white, then the pellet was re-suspended in 3 ml "Buffer 2" and 50 µl proteinkinase K 
followed by 2 h incubation at 60°C while rocking at 95 rpm. If a clear, transparent DNA 
solution was not obtained after this step, the incubation was extended for another 30 
minutes. The solubilzed DNA was then transferred to labelled 15 ml tubes, and 1.8 ml of 
"Buffer 3" were added. The solution mixed by agitation and incubated for 5 min on ice, 
followed by centrifugation for 15 min at 10000 xg. The supernatant was transferred to a 
new, labeled 15 ml tube and the two volumes (9.6 ml) of 96% ethanol added. Inverting 
the tube resulted in precipitation of the DNA. After centrifugation for 3 min at 10000 xg 
the supernatant was discarded, the pellet transferred to a labeled 2 ml tube previously 
filled with 1 ml 70% ethanol, stirred and centrifuged for 2 min at 10000xg. The 
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supernatant was discarded, the pellet dried in the tube with open lid until the ethanol was 
completely evaporated. Finally, 500 µl TE (1x) buffer was added to dissolve the DNA. 
 
For small volumes of blood, DNA was extracted with the PEQLAB DNA isolation 
system (PEQLAB Biotechnology GmbH, Erlangen, Germany). All procedures were 
conducted according to the protocol provided with the kit. 
 
DNA samples were stored either at 4°C or at -20°C. The quality and the concentration of 
the DNA were measured when all DNA was dissolved. The genomic DNA was quantified 
using PicoGreen (Molecular Probes Europe BV, Leiden, The Netherlands). The 
automated concentration measurement was carried out on a TECAN SPECTRO FLUOR 
fluorescence microplate reader (Tecan Deutschland GmbH, Crailsheim, Germany). 
 
2.4.2 Plate design 
 
 
Individual DNA samples were arranged in 96 well microtiter plates. Each 96 well plate 
contained a maximum of 93 DNA samples. Two wells contained the same CEPH (Centre 
d'Etude du Polymorphisme Humain, Paris, France) cell line (as a control in the diallelic 
discrimination assays), located for each plate layout in the same position. Negative 
controls (wells containing no DNA) were increased from one to four wells over the course 
of plate production and were present at the same position for each plate layout. Four 96 
well plates were merged into one 384 well plate. Whenever family samples were 
involved, the plates were designed to keep the families on one plate. The plate-layout with 
individual identification through barcodes was entered to the database system before the 
plate was produced. Each plate received an identification number. Application to 96 and 
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384 deep well plates (ABgene, Epsom, UK) and adjustment of the concentration was 
performed with the aid of a TECAN Genesis RSP 150 multipipetting robot (Tecan 
Deutschland GmbH, Crailsheim, Germany). An aliquot of DNA -TE solution containing 2 
ng (for diallelic discrimination assays) or 5 ng (for sequencing) DNA was then distributed 
via 96- and 384-channel Robbins Scientific Hydra microdispensers (Dunn Labortechnik 
GmbH; Asbach, Germany) to the 96 or 384 well microplates (Costar Corning 
Incorporated; Cambridge MA, USA, Greiner Bio-One GmbH, Frickenhausen; Germany). 
The DNA plates were dried at 60°C, and the plates then were heat sealed with a 
ABGENE ALPS 300 (ABgene, Epsom, UK) for storage at –20°C. 
 
2.4.3 Whole Genome Amplification (WGA) plate preparation 
 
 
The purpose of making the WGA plate is to perform unlimited genetic tests from limited 
source material. Genomiphi DNA Amplification Kit (Amersham Biosciences; Freiburg, 
Germany) was used for preparing WGA plates. The Genomiphi method utilizes 
bacteriophage Phi29 DNA polymerase to exponentially amplify single- or double-
stranded linear DNA templates during an isothermal strand displacement reaction. 
Microgram quantities of DNA are generated from nanogram amounts of starting material 
after an overnight incubation. One microlitre of 10-400ng of DNA samples was mixed 
with the sample buffer, which contained random hexamers and heated at 95°C for 3 
minutes. The mixture was quickly cooled on ice. Enzyme mix (1µl) was diluted in 9µl of 
reaction buffer and added to cooled sample. After incubating the sample at 30°C for 16 
hours, the sample was heated at 65°C for 10 minutes and cooled down to 4°C. This 
sample was now ready for genotyping. 
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2.5 Diallelic genotyping 
 
 
2.5.1 Taqman assays 
 
 
For the analysis of allele status at a known SNP position in a large group of DNA 
samples, the method of diallelic genotyping (5’ nuclease assays) was applied. The 5' 
nuclease PC assay detects the accumulation of specific PCR product by hybridisation and 
cleavage of a double-labeled fluorogenic oligonucleotide during the amplification 
reaction. Besides the forward and reverse primer, two oligonucleotides (called probes), 
one for each allele, are involved in the reaction. The probe has a reporter fluorescent dye 
attached at the 5' end and a quencher dye at the 3' end. The two probes have reporter dyes 
with fluorescent emission at different wavelengths. During the PCR reaction, several 
events occur. First, each TaqMan MGB probe anneals specifically to a complementary 
sequence between the forward and reverse primer sites. When the probe is intact, the 
proximity of the reporter dye to the quencher dye results in suppression of the reporter 
fluorescence. Second, AmpliTaq Gold DNA polymerase cleaves only probes that are 
hybridized to the target. Third, cleavage separates the reporter dye from quencher dye, 
which results in increased fluorescence by the reporter.  The increase in fluorescence 
signal occurs only if the amplified target sequence is complementary to the probe 101. 
Mismatches between a probe and target reduce the efficiency of probe hybridization. 
Furthermore, AmpliTaq Gold DNA polymerase is more likely to displace a mismatched 
probe without cleaving it, which does not produce a fluorescent signal. After separation 
from the quencher, the dye becomes fluorescent (Fig. 2.5.1). Visualization takes place 
through laser scanning technology (ABI PrismⓇ 7700 Sequence Detection System or ABI 
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Prism 7900HT Sequence Detection System). In each cycle, fluorescence increases, 
proportionally to the rate of probe cleavage. To induce fluorescence, laser light is 
distributed to the 96 or 384 sample wells via a multiplexed array of optical fibers. The 
resulting fluorescent emission returns via the fibers and is directed to a spectrograph with 
a charge-coupled device (CCD) camera. The fluorescent dyes employed for the analysis 
are TET (tetrachloro-6-carboxyfluorescein) and FAMTM (6-carboxyfluorescein) and VICⓇ 
(trade name by Applied Biosystems) and the quencher TAMRA (6-
carboxytetramethylrhodamine). The systems employed (Applied Biosystems TaqManⓇ 
technology und TaqManⓇ -MGB technology) allow 96 well and 384 well platforms. The 
integrated software depicts the fluorescent status for each well in a diagram and allows 
assigning an allele calling to each well. A general setting of the software is that the TET 
(VICⓇ for TaqManⓇ -MGB probes) allele is always called 1, FAMTM -allele 2. Each well 
of the 96 well or 384 well plate results in a dot on the diagram according to the 
fluorescent intensity of the reporter dyes. The distribution is a cloud of the dots for each 
homozygous allele 1/1 or 2/2 calling group, and the heterozygous 1/2 calling group. 
 
In contrast to the TaqManⓇ probes, the TaqManⓇ -MGB probes contain a minor groove 
binder (MGB), which attaches to the minor groove of duplex DNA and by this stabilizes 
hybridisation products and allows shorter probes. Furthermore, a non-fluorescent 
quencher replaces the TAMRATM quencher, reducing the background fluorescence and 
improving the spectral discrimination. Different levels of automation were employed in 
the diallelic genotyping. Many allelic genotyping assays were ordered in a ready to use 
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status (Assay-on-Demand, Applied Biosystems Inc., Foster City, CA, USA), or were 
designed from a sequence by a company (Assay-by-Design Applied Biosystems Inc., 
Foster City, CA, USA) (both TaqManⓇ-MGB technology). Both need no further 
optimisation. Several of the assays employed were self-designed using the TaqMan ® 
technology. The oligonucleotides were manufactured and labelled with fluorescent dyes 
by a company (Eurogentec S.A., Seraing, Belgium) according to the defined sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5.1 The principle of Taqman diallelic genotyping  
 
 
 
For the design of oligonucleotides employed in the diallelic assay, the program Primer 
Express 2.0 (Applied Biosystems Inc., Foster City, CA, USA) was used. The guidelines 
proposed in the program description were applied 102 103. The polymorphism was in the 
middle or the last third of the probe (minimum 5 bases before the end of the probe). The 
probe was not allowed to start with a guanine (G) as the first base. The required melting 
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temperature (Tm) for the probes was about 70°C, with a flexible range of ±2°C. The 
difference in Tm between the probes was not larger than 0.5°C. The sequence of the 
probes belonging to one assay was allowed to vary in length, with a maximum length of 
40 bases. The minimum length was 17 bases. The primer Tm was about 10°C below the 
Tm of the probes; therefore, the optimal Tm for primers was between 58 to 60°C. Primers 
were not selected from repeat masked regions or regions with other SNPs. The average 
amplicon length varied between 50 to 150 bp. Where the SNP needed verification, the 
amplicon was chosen to be close to 150 bp or even longer to allow a clean sequencing 
product around the SNP. The reverse primer was allowed to overlap with the probe, but 
not to reach the SNP. Primers with high variation in the bases at the 3’end were allowed. 
A thymidine was not allowed in the last 3’ position and three same bases in a row within 
the last third of the oligonucleotide were not allowed. TaqManⓇ probes were labelled 
with the fluorescent dyes FAMTM or TET and with the quencher TAMRATM. 
 
 
2.5.2 SNPlex assays 
 
 
The SNPlex genotyping system uses Applied Biosystems oligonucleotide ligation assay to 
achieve allelic discrimination and target amplification. Each assay includes three SNP-
specific ligation probes. Two of the probes are allele-specific oligos (ASOs).  These are 
designed specifically for the polymorphism by having the discriminating nucleotide on 
the 3’ end. Each ASO probe contains one of the 96 unique ZipCode sequences for 
ZipChute probe binding. The third probe is a locus-specific oligo (LSO). Its sequence is 
common to both alleles of a given locus and anneals adjacent to the SNP site on its target 
DNA. A set of Universal ASO/LSO linkers is needed. Each ASO is ligated to a universal 
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ASO-specific linker, which contains a PCR primer sequence corresponding to the 
universal forward primer and a partial ZipCode sequence. The ASO linkers anneal to the 
universal ZipCode sequence of the ASO probes. Another linker is ligated to the LSO and 
has a universal sequence that is compatible with all LSOs, which includes a partial 
binding site for a universal reverse primer. (Fig 2.5.2a) 
 
 
 
 
 
 
 
 
 
Fig 2.5.2a interaction between SNP-specific probes and universal linkers 
 
ZipChute probes are one of the key components of the SNPlex assays. Each Zipchute 
probe has a ZipCode-binding sequence, mobility modifiers, which enable size separation 
during electrophoresis, and a fluorescuent label. (Fig 2.5.2b) 
 
 
 
 
 
  
                 Fig 2.5.2b the parts of a ZipChute probe 
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The processes required to perform the SNPlex assay are shown in Fig 2.5.2c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  Fig 2.5.2c SNPlex Assay Flowchart 
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After the reaction, plates are loaded onto 3730xl instrument. All the data were processed 
using GeneMapper Software 4.0. 
 
2.6 Mutation detection in candidate genes 
 
 
2.6.1 PCR optimisation 
 
 
The strategy for the optimization of PCR conditions for different primer-pairs was 
developed on the basis of standard PCR protocols 104 105. First we diluted the 
oligonucleotide to a storage concentration of 100 pmol/µl with DDW, and then made a 
working solution of 20 pmol/µl. The reaction solution contained the following reagents: 
2.5 µl Qiagen Buffer (10 x concentrated) 0.5 µl dNTP (10 mM), 0.2 µl primer forward; 20 
pmol/µl, 0.2 µl primer reverse; 20 pmol/µl 1.0 µl MgCl2 (25 mM) 0.15 µl Taq polymerase 
(QIAGEN GmbH; Hilden, Germany) and DDW, to a final amount of 25.0 µl per reaction. 
Five ng of liquid DNA were used. Also the amount of MgCl2 could be changed according 
to the conditions needed. The PCR reaction was set up in a T1 Gradient PCR machine 
(Whatman Biometra GmbH, Göttingen, Germany) with the following cycle program: 
96°C - 10 min, (96°C - 1 min; 64°C - 1 min [– 0.5 °C per step]; 72°C - 1 min) 16x, (96°C 
- 1 min; 56°C - 1 min; 72°C - 1 min) 15x, 72°C - 10 min. The gradient covered the 
temperatures up to 5°C higher and lower than the annealing temperature given in the 
protocol. A range of temperatures could be tested at one time in this way (e.g. a range 
from 59°C to 69°C in the example above). Five µl of PCR products together with 2 µl of 
2-times concentrate loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 
30% glycerol in water) were applied to a 1.5% agarose gel. A 100 bp ladder (Invitrogen 
GmbH, Karlsruhe, Germany) was applied next to the PCR products; electrophoresis 
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conditions were 150 V for 50 min. A picture was taken under UV light and observed 
bands of PCR products were compared to expected product length. Quality criteria were 
one clear band at the correct length without smear, no double bands, and a low amount of 
primer-dimer.  
 
2.6.2 Sequence analysis 
 
 
The solutions for the sequencing reaction were prepared according to previously 
optimized conditions. The solution was applied to a 96 well with 5ng liquid DNA in each 
well. Five micro liters of PCR product were mixed with 2 µl 2-times loading buffer and 
tested on a 1.5% agarose gel (in 300 ml TBE, 1% ethidiumbromide, 150 V for 50 min). 
After finishing the PCR reaction, digestion was required to be remove the unwanted 
primer-dimers and free dNTPs in the PCR product before sequencing. For a highly 
concentrated PCR product, a 1:5 dilution with DDW was necessary before the digestion. 
The enzymatic digestion was performed in a new plate with 8 µl PCR product at the 
following conditions: 0.30 µl SAP (Shrimp Alkaline Phosphatase; 1 U/µl) 0.15 µl ExoI 
(Exonuclease I; 10 U/µl) 1.55 µl DDW adding up to 2.0 µl complete reaction mix, with 
following incubation conditions: 37°C - 15 min, 72°C - 15 min. The chemicals used for 
sequencing were from the BigDye Terminator Ready Reaction kit (Applied Biosystems 
Inc., Foster City, CA, USA) based on fluorescent terminator dNTPs. Two microliters of 
digested PCR product were used for the sequencing reaction, 1.0 µl primer (forward or 
reverse); 3.2 pmol/µl, 1.0 µl BigDye version1.0 Ready Reaction Mix from the kit, and 6.0 
µl DDW for a reaction volume of 8.0 µl. The same reaction was performed with the 
reverse primer. The following cycle protocol for the sequencing reaction was used: 95°C - 
5 min; (95°C - 1 min; 50°C - 15 sec; 60°C - 4min) 25x; 60°C -.5 min. Sample cleanup 
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was performed with Sephadex spin columns. The Sephadex spin column plates (MAHVN 
4550) were prepared by adding Sephadex powder (G50 Superfine) with the aid of a 
Multiscreen Column loader (gel exclution products obtained from Amersham 
Biosciences, Freiburg, Germany), 300 µl DDW were added to each column. The plate 
was incubated at room temperature for 2 hours. Centrifuge the plate at 2100 r/m for 5 
minutes and wash the plate with 150 µl DDW and centrifuge once again at 2100 r/m for 5 
minutes. Then add 10 µl of DDW to the sequencing produces, after short centrifuge, 
pipetted it to the centre of the spin columns. The plate was fitted to a MicroAmp ® 
Optical 96-Well Reaction Plate (Applied Biosystems Inc., Foster City, CA, USA). After 
centrifugation at 2100 r/m for 5 min, the flow through contained the purified sequencing 
product. The sequence detection was performed with an automated 96-capillary 
fluorescence detection system ABI PRISM ® 3700 DNA Analyzer (Applied Biosystems 
Inc., Foster City, CA, USA), for fluorescent labelled DNA fragments. For the sequence 
analysis, chromatograms were aligned and compared to the consensus sequences using 
Sequencher Version 4.0.5 (Gene Codes Corporation, Ann Arbor, MI, USA) and InSNP 
program 106. 
 
 
2.6.3 Mutation detection in candidate gene 
 
 
2.6.3.1 AGR2 and AGR3 gene on chromosome 7 
 
 
A total of 21 pairs of primers were design to cover all exons and the promoter region of 
the AGR2 and AGR3 genes. Amplification was performed with an ABI GeneAmp ® PCR 
System 9700 (Applied Biosystems Inc., Foster City, CA, USA) using the following 
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thermoprofile: 96°C - 10 min, (96°C - 1 min; 59-68.7°C - 1 min [–0.5 °C per step]; 72°C - 
1 min) 16x, (96°C - 1 min; 51.2-60.7°C - 1 min; 72°C - 1 min) 25x, 72°C -10 min (Table 
2.6.3.1a, Table 2.6.3.1b) 
 
Table 2.6.3.1a Primers and PCR protocol of AGR2 gene 
Exon Primer Mixture Cycle  amplicon 
Celera 
promoter 
F:AGTTTAGGTGGAAATTGCTAATGGC 
R:CTCATGGCTTAATGACTTTGGGTT 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-59.7° 
1min-72° 1min (16)/96° 1min-
51.9° 1min-72° 1min (20)/72° 
10min 
746bp 
Celera 
exon1 
F: TCGTCTGGCTCCACTTACTCAGA 
R: ACAGGCAATAACAAATGCTGGC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-59.7° 
1min-72° 1min (16)/96° 1min-
51.9° 1min-72° 1min (20)/72° 
10min 
759bp 
Celera 
exon2 
F: GACTAAGTGATCCTTTCATTCGGC 
R: CTAGTGAATGGGCTTGTGCTTGT 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.3) R(0.3)/Taq 
Polymerase 0.15/DNA 5/Water 
11.25 
96° 10min/96° 1min-59° 1min-
72° 1min (16)/96° 1min-51.2° 
1min-72° 1min (20)/72° 10min 
646bp 
Ncib 
promoter 
F: GAACTCTGTGGAGGGAAGTTGCT 
R: CCACCCACTAGTGCTGCATTTAC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-64.5° 
1min-72° 1min (16)/96° 1min-
56.6° 1min-72° 1min (20)/72° 
10min 
607bp 
Ncbi 
exon1  
F: AATCTGCCCACGGAGCAGA 
R: GAGGCCCGAATTCACTCCAG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
480bp 
Ncbi 
exon2-4 
F: CAACCTGCAGACCCTGAAGACT 
R: GAACCCTGGCCCTAAGGCTA 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-64.5° 
1min-72° 1min (16)/96° 1min-
56.6° 1min-72° 1min (20)/72° 
10min 
780bp 
Ncbi 
exon5 
F: TTGTTCACTGCACCATCCCTAGT 
R: GGAAGCAATCCCAGTTAATGCA 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
482bp 
Ncbi 
exon6 
F: GCCGGAAATGGACAGATTCTT 
R: ACGTGGCAAGGGACAGTGG 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.75) R(0.75)/Taq 
Polymerase 0.15/DNA 5/Water 
10.35 
96° 10min/96° 1min-60.8° 
1min-72° 1min (16)/96° 1min-
53° 1min-72° 1min (20)/72° 
10min 
239bp 
Ncbi 
exon7 
F: ACAGCTGTTGATGTTTCCAGCC 
R: GAGGCGTCCCTAAGCCTAGC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-68° 1min-
72° 1min (16)/96° 1min-60° 
1min-72° 1min (20)/72° 10min 
405bp 
Ncbi 
exon8-2 
F: ATGCCAGCCTGAGTGGGAGT 
R: CTGAAGGAGAAAGCTACTTGCCAG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-64.5° 
1min-72° 1min (16)/96° 1min-
56.6° 1min-72° 1min (20)/72° 
10min 
835bp 
Ncbi 
exon8-3 
F: GAGTCAACTCTGGCCAGGAACTC 
R: ACCTTATTTCACGTCCGCCC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 
15.45 
96° 10min/96° 1min-64.5° 
1min-72° 1min (16)/96° 1min-
56.6° 1min-72° 1min (20)/72° 
10min 
924bp 
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Table 2.6.3.1b Primers and PCR protocol of AGR3 gene 
Exon Primer Mix Cycle amplicon 
Celera 
promoter 
F: AACCGTTCCTGTTTCCTGGG 
R:TAATGTTTGGCTGAAGTTCAGCAC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
427bp 
Celera 
exon1 
F:TCTTGTTTCTATGCAGGTGAGGTTG 
R: TGGTTACAGGCCTACAGCAGCT 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
581bp 
Ncbi 
promoter 
F:GGAACTGAAGGACAAGAATCCTCC 
R: CACGAAGCCTGCTTCTGAACC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.1) R(0.1)/Taq 
Polymerase 0.15/DNA 5/Water 15.65 
96° 10min/96° 1min-62° 1min-
72° 1min (16)/96° 1min-54.2° 
1min-72° 1min (20)/72° 10min 
260bp 
Ncbi 
exon1 
F: TGACTTCTCACCAACTGAGCATGT 
R: TGCTAGTTGATTTGATTCACTGCC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68° 1min-
72° 1min (16)/96° 1min-60° 
1min-72° 1min (20)/72° 10min 
541bp 
Ncbi 
exon2 
F: AGCCAACAGCTTGATGGCTTAG   
R: GAGGGTTCAGAGCTGGAAGGAT 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68° 1min-
72° 1min (16)/96° 1min-60° 
1min-72° 1min (20)/72° 10min 
522bp 
Ncbi 
exon3 
F: CTCCTGGGTTCAAGCGATTCT       
R: TTGCTGAGCGCCTTCTTAGC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.1) R(0.1)/Taq 
Polymerase 0.15/DNA 5/Water 15.65 
96° 10min/96° 1min-62° 1min-
72° 1min (16)/96° 1min-54.2° 
1min-72° 1min (20)/72° 10min 
489bp 
Ncbi 
exon4 
F: GACAAAGTGGCAATAGGCCAAT  
R: GTGCCTGTAGTCCCAGCTACTTG 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.75) R(0.75)/Taq 
Polymerase 0.15/DNA 5/Water 10.35 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
438bp 
Ncbi 
exon5 
F: CACCTTGTTGGTTAGGCTGGTC     
R: GATAATGGCCTCTGGCTACATCC 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.75) R(0.75)/Taq 
Polymerase 0.15/DNA 5/Water 10.35 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
771bp 
Ncbi 
exon6 
F: GGATGTAGCCAGAGGCCATTATC 
R: GGTGGGAGCTAGAAGTTGGCA 
Buffer 2.5/Q buffer 5/dNTP 
0.5/MgCl 1.0/Primer F(0.3) 
R(0.3)/Taq Polymerase 0.15/DNA 
5/Water 11.35 
96° 10min/96° 1min-60.8° 
1min-72° 1min (16)/96° 1min-
53° 1min-72° 1min (20)/72° 
10min 
605bp 
Ncbi 
exon7 
F: TCATAGACGAATTCCCATGTTCAA 
R: CTCCACTATAACTCTTGGCAGGCT 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.1) R(0.1)/Taq 
Polymerase 0.15/DNA 5/Water 15.65 
96° 10min/96° 1min-63.2° 
1min-72° 1min (16)/96° 1min-
55.4° 1min-72° 1min (20)/72° 
10min 
416bp 
 
 
2.6.3.2 Candidate genes on chromosome 12 
 
A total of 29 pairs of primers were design to cover all exons and the promoter region of 
the LOC115749, BC042855 and FLJ32549 genes. Amplification was performed with an 
ABI GeneAmp ® PCR System 9700 (Applied Biosystems Inc., Foster City, CA, USA) 
using the following thermoprofile: 96°C - 10 min, (96°C - 1 min; 59-68.7°C - 1 min [–0.5 
°C per step]; 72°C - 1 min) 16x, (96°C - 1 min; 51.2-60.7°C - 1 min; 72°C - 1 min) 25x, 
72°C -10 min (Table 2.6.3.2a, 2.6.3.2b, 2.6.3.2c) 
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Table 2.6.3.2a Primers and PCR protocol of LOC115749 gene 
Exon Primer Mixture Cycle  amplic
on 
BC03 
Exon1_1 
F: GATCCGCAACAGAGTACGCAGT 
R:CTTGAGGATGTGGTTCTCAGAGTTG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
542bp 
BC03 
Exon1_2 
F: AGCCGACCTAGCGTCGATTC 
R: AGGGAGCTCGGTTCTCAAACC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
694bp 
BC03 
Exon2 
F: GCTGTTAGCTTTGGGGGATTTATT 
R: ACTGTCCGCATCTTTCAATGTGT 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.3) R(0.3)/Taq 
Polymerase 0.15/DNA 5/Water 11.25 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
417bp 
BC03 
Exon3 
F: GTGTGAGCCACCGTGCTTG 
R:CACAGAACCAGAGCTCAACAGATG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
574bp 
BC03 
Exon3b_1  
F: CCATGAAGGACAGGCACAATACTT 
R: TCATTTCCATTCCCATTGCACT 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-65.7° 1min-
72° 1min (16)/96° 1min-57.8° 
1min-72° 1min (20)/72° 10min 
550bp 
BC03 
Exon3b_2 
F: GAGCTCTCAGTCTGCACCAACAA 
R: CAAAGTGCTGGGATTACAGGAATG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
539bp 
BC03 
Exon3c 
F: AAGGTAGGGGGAATTGATCTTCAG 
R:CCCATGCAACTCTATCATACATCATC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
174bp 
BC03 
Exon4 
F: CCAGGGACAGTGAGAGTATTCCTG 
R: ACCCAATGCATGGCAGCTACT 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.75) R(0.75)/Taq 
Polymerase 0.15/DNA 5/Water 10.35 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
657bp 
BC03 
Exon4b 
F:TGTTATGTGCTAAGCACTGTTGAAGC 
R:CAGGTGTGGGATATAATCTCATGGTT 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
574bp 
BC03 
Exon5 
F: GGCCTAACTGGCATCTCCCA 
R: CTCCGGTAGCTGAAGCATGAGA 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-65.7° 1min-
72° 1min (16)/96° 1min-57.8° 
1min-72° 1min (20)/72° 10min 
628bp 
BC03 
Exon6 
F: GTGCTGGGATTACAGCATGAGTG 
R: ACTATGGGAAATTCTGGCGGAG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
665bp 
BC03 
Exon7 
F: TTACCCAAATCTCCCTTAAATCCAG 
R: ACCCATTAGACCCCTGCTATGG 
Buffer 2.5/Q buffer 5/dNTP 
0.5/Primer F(0.75) R(0.75)/Taq 
Polymerase 0.15/DNA 5/Water 10.35 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
773bp 
BC03 
Exon89_1 
F: ACCAGCCTGGGCAATATAGTGAG 
R: GTGGATCCCAATCCGAGATTTC 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
732bp 
BC03 
Exon89_2 
F:GTACTTGAGATGGTCTCCAAAACTGG 
R: GGATGGTGTCTGTGGGACAGAG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
642bp 
BC03 
Exon10 
F:GTAGTGAGGGCCTCAGTCTAGATTTG 
R:TCTTCTAAATATTGGACCATGTTGCA 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
373bp 
BC03 
Exon11_1 
F: GAGCCTCTGCTCATACTGTGGTG 
R: TCTTTTGCCCAATGGCATAAAG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
610bp 
BC03 
Exon11_2 
F: TGCAGAAAAGGCTCCCATTG 
R: CCCGGCATCCTATTGCTTAAG 
Buffer 2.5/dNTP 0.5/MgCl 
1.0/Primer F(0.2) R(0.2)/Taq 
Polymerase 0.15/DNA 5/Water 15.45 
96° 10min/96° 1min-68.7° 1min-
72° 1min (16)/96° 1min-60.7° 
1min-72° 1min (20)/72° 10min 
514bp 
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Table 2.6.3.2b Primers and PCR protocol of BC042855 gene 
Exon Primer Mix Cycle amplicon 
BC04 
Exon1 
F: ACTTCCGGGTTCTGAGGGAAC 
R: CCAGGGCTGACGTCACGTT 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
499bp 
BC04 
Exon3 
F: GTTGTATCCCGAACTTTTCCTCAAC 
R: CCCAGCAAAAGAATAAATGCATG 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68.7° 
1min-72° 1min (16)/96° 1min-
60.7° 1min-72° 1min (20)/72° 
10min 
586bp 
BC04 
Exon4 
F:AAAGGGATTCTTCACATGAATTGATG 
R: TGAATTGATGTGAGCACACCCA 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 1min-
72° 1min (16)/96° 1min-60° 
1min-72° 1min (20)/72° 10min 
262bp 
BC04 
Exon5 
F: CTAGTTTTTTCTCAGGCAGCCAAG 
R:TTTATCGAATTTACCTCCCTCATGAG 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 1min-
72° 1min (16)/96° 1min-60° 
1min-72° 1min (20)/72° 10min 
742bp 
 
Table 2.6.3.2c Primers and PCR protocol of FLJ32549 gene 
Exon Primer Mix Cycle amplicon 
B03 
Exon1 
F: GCCCTTATCCGCGTCTTCTCTA 
R: GTCGAGCCTGCGACTAGAAGTG 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
583bp 
B03 
Exon2 
F: TGCATGTTGGTAGGTGTTTGGTAC 
R: CTCTGAGCTTGTGTGGGATTGATAG 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
425bp 
B03 
Exon3 
F:TTAGAAAAATGTCAGTGTGGCAAGTG 
R:GAAAGAGGCATGAATGGATGTAAACT 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
960bp 
B03 
Exon3a 
F: GAAAATATGATGCTGCCAATGTGTC R: 
TGGTAGCCCATGACCACTTCC 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
636bp 
B03 
Exon3b 
F: CATCCATTCATGCCTCTTTCAGA 
R: ACCCATGGCTATTAAAGCTGCC 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
558bp 
B03 
Exon3c 
F: GTCAGATTGGTAGCATGACGTAAGG 
R: ACCCAGTAAAACAGTGGCTCCAC 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
736bp 
B03 
Exon4 
F: ACTCCCCACAAAAGCCCTGTAG 
R:GCAGAATTCACTCTCTAGGGACAAAG 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
580bp 
B03 
Exon4a 
F: TTAGACGTGCGGCGAGAATG 
R:GTCATTTGGTCATTAAACTCTTAGAGCC 
Buffer 2.5/dNTP 0.5/MgCl 
2.0/Primer(10µM) F(0.5) 
R(0.5)/Amplitaq Gold Polymerase 
0.12/DNA 5/Water 13.88 
96° 10min/96° 1min-68° 
1min-72° 1min (16)/96° 
1min-60° 1min-72° 1min 
(20)/72° 10min 
1012bp 
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2.7 Internal database 
 
 
The large numbers of individuals with DNA samples, phenotype description, family 
information and genotype information was handled through an internal SQL database system 
107. Every sample had a unique identification number. The following information was 
collected for each patient: age, gender, pedigree information, and phenotypic trait. The plates 
with DNA samples were identified through barcode system. The quantity and concentration 
information of the samples were also included in the database.  Information about diallelic 
genotyping assays such as oligonucleotide sequences (not available for Assay-on-Demand 
assays), chromosomal position, and genetic variants were also entered in the database. After 
genotyping was performed, the results were entered into the database and automatically 
linked to the individual sample through the barcode of the plate. The database allowed 
exporting data of individuals, within an analysis population, with their pedigree information; 
phenotypic trait and genotype information from a set of self selected SNP markers. The 
export format was the appropriate format for a selection of analysis programs (LINKAGE 
PREFILE). Furthermore, sets of application tools were used to get the information about the 
assays and the plates. Additional applications helped to enter and edit sample information, 
create plate templates, to control robots to make plates and to measure DNA concentration. 
 
Integrated to the database system was a test for Mendelian inheritance errors. This application 
was part of the SNP genotyping data import to the database. It was utilized on each SNP 
marker and all populations for which the marker had been genotyped. All inheritance errors 
were shown in a list with all family members and their genotyping data for that assay. The 
positions of the family members in the fluorescence diagram of the plate containing the 
family were seen through the linked plate-view 107. A few families with Mendel errors were 
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normal and acceptable. For SNP markers with a high number of inheritance errors, the SNP 
marker was excluded from the analysis when the assay was evaluated as not reliable. For 
sample populations of single individuals, genotyping results were subjected to assessment of 
HWE by a χ2 -test at the 1% significance level. This test was applied as well to genotypes 
from families, however a slight imbalance could be expected in this situation.  
 
 
2.8 Statistical analysis 
 
 
Before the genetic analysis, each marker was tested for Hardy-Weinberg Equilibrium (HWE) 
108 109 in the control population. Family-based analyses were performed using the 
transmission disequilibrium test (TDT) 84 in trios, using TRANSMIT 51 and GENEHUNTER 
81. Haplotype frequency estimates among singletons were obtained using an implementation 
of the EM algorithm (HAPMAX) 110. Significance testing of haplotype frequency differences 
was also performed with HAPMAX, making use of the fact that twice the log-likelihood ratio 
between two nested data models approximately follows a χ2 distribution with k degrees of 
freedom, where k is the difference in parameter number between the two models. 
Significance assessment of associations with or between single locus genotypes was 
performed using χ2 or Fisher's exact test for 2×3 contingency tables. All other statistical 
calculations were performed with SPSS.  
 
Allele and genotype frequencies for each SNP were calculated from all unrelated control 
individual. In multiplex family, only one affected individual was selected randomly. In 
monoplex families, each affected individual was selected. Case-control analysis was 
performed for alleles and genotypes using contingency tables. Pearson’s χ2 was used for 
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measuring the association between the disease trait and the SNPs. The significance at the 95% 
confidence interval is given as p-value. 
 
Family based transmission distortion was analyzed by using transmission disequilibrium test 
(TDT). This test is based on a comparison of alleles transmitted from parents to affected 
offspring against the alleles that were expected to be transmitted from the population 
frequency in the parent generation. This was calculated by using GENEHUNTER program, 
which calculated the TDT by comparing alleles transmitted from parent to offspring with 
alleles untransmitted. 
 
Linkage disequilibrium (LD) was calculated by employing the HAPMAX program. The 
measure estimates the difference between the number of two marker haplotypes observed and 
the one expected under the assumption of independence in segregation of markers using the 
correlation coefficient. 
 
For the candidate genes with significant association signals, odds ratio (OR) was calculated as 
a measure of increased risk of affection with a certain SNP variant. 
 
2.9 cDNA amplification 
 
 
2.9.1 Amplification of AGR2 cDNA 
 
 
The public databases and Celera Discovery Systems were reviewed in order to establish gene 
models for the AGR2 and AGR3 genes. For AGR2, two additional 5’ exons were annotated. 
The presence of the additional 5-prime exons was investigated through RT-PCR in the 
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Clontech multiple tissue panels I and II (East Meadow Circle, Palo Alto, U.S.A.), using 
standard supplier’s protocols. For the gene model evaluation of AGR2, the following primers: 
were used for the short form: AGRf5: TCA ACT CTG GCC AGG AAC TC; AGRr5: TAC 
AGC ACC ATA GTC CAG GG and 2) for the long form (designed on the basis of the NCBI 
and Celera gene models): AGRf11: CGA CTC ACA CAA GGC AGG T; AGRr11: GCT 
GTA TCT GCA GGT TCG T. 
 
2.9.2 Amplification of cDNA from candidate genes on chromosome 12 
 
 
Primers were designed according the public database. RT-PCR were performed in the 
Clontech multiple tissue panels I and II (East Meadow Circle, Palo Alto, U.S.A.). The 
following primers were used: LOC115749 gene: BC_03_exF1: CCG AGT CAT CAC GCC 
TGA AC; BC_03_exR1: TCG GAT TGG GAT CCA CAA AGT; BC042855 gene: 
B04_RNA_F1: GTC GAC TTT CCA AAG CGC TG; B04_RNA_R1: TGG ATT GAG ACT 
GAG CAT GCC and FLJ32549 gene: B03_RNA_F1: AAG GTC TAT CAC AGC CTC ACC 
TAC C; B03_RNA_R1: CTT TCA GGA GAT GAC ACA GGA CG. The reaction solution 
contained the following reagents: 2.5 µl Buffer (10 X concentrate) 0.5 µl dNTP (10 mM), 0.5 
µl primer forward; 10 pmol/µl, 0.5 µl primer reverse; 10 pmol/µl 2.0 µl MgCl2 (25 mM) 0.15 
µl Amplitaq Gold polymerase (Applied Biosystems; Weiterstadt, Germany) and DDW, to a 
final amount of 25.0 µl per reaction. Five µl of liquid cDNA were used. The PCR reaction 
was set up with the following cycle program: 96°C - 10 min, (96°C - 1 min; 68°C - 1 min ; 
72°C - 1 min) 16x, (96°C - 1 min; 60°C - 1 min; 72°C - 1 min) 24x, 72°C - 10 min. Five µl 
PCR products together with 2 µl of 2 X concentrate loading buffer (0.25% bromophenol blue, 
0.25% Xylene Cyanol FF, 30% Glycerol in Water) were applied to a 1.5% agarose gel (300 
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ml Tris borate EDTA (TBE), 3 µl ethidium-bromide). A 100 bp ladder (Invitrogen GmbH, 
Karlsruhe, Germany) was applied next to the PCR products; electrophoresis conditions were 
150 V for 50 min. A picture was taken under UV light.  
 
2.10 Rapid Amplification of cDNA Ends (RACE) 
 
 
Rapid amplification of cDNA ends (RACE) is a polymerase chain reaction (PCR)-based 
technique which was developed to facilitate the cloning of full-length cDNA 5'- and 3'-ends 
after a partial cDNA sequence has been obtained by other methods. Marathon cDNA 
amplification is a method for performing both 5’ and 3’ rapid amplification of cDNA ends 
from the same template (Fig 2.10a). A Marathon-Ready cDNA kit (kidney) was used to 
confirm if other transcription products existed in the LOC115749 gene. Marathon-Ready 
cDNAs are premade “libraries” of adaptor-ligated ds cDNA ready for use as templates in 
Marathon cDNA amplification. The first and the second strand cDNA synthesis were done by 
the company (Fig 2.10b). Primers were designed by using standard supplier’s protocols. The 
following primers were used for 5’ RACE in LOC115749 gene: BC_GSP_F1: GCA GGG 
AAA TCT CGG ATT GGG ATC CAC. The reaction solution contained the following 
reagents: 5µl 10*cDNA PCR reaction buffer, 1µl dNTP (10mM), 1µl Advantage 2 
polymerase mix (50*), 5µl Marathon-ready cDNA (Kidney, 1:5 diluted), 1µl AP1 Primer 
(10mM), 1µl EB_GSP_F1 primer (10mM) and 36µl DDW. The PCR reaction was set up with 
the following cycle program: 94°C 30sec, (94°C 5sec, 72°C 4min) 5x, (94°C 5sec, 70°C 
4min) 5x, (94°C 5sec, 68°C 4min) 30x. 
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Fig 2.10a Overview of Marathon procedure  
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       Fig 2.10b Overview of Marathon cDNA ready kit procedure 
 
 
 
 
 
2.11 Cell culture, reporter gene constructs and dual luciferase reporter gene assay 
 
 
 
HEK 293 cells were purchased from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). The cells were cultured in DMEM + 10% 
fetal calf serum. One day prior to transfection, cells were seeded at a density of 5 x 105 
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cells/2 ml on 6-well plates. Transfections were performed with Fugene 6 (Roche, 
Switzerland) according to the manufacturer’s manual by using 0.08 µg of the target 
plasmid and 0.02 µg of the pRL-TK reference plasmid (Promega, Mannheim, Germany) 
for the reporter gene assays. The constructs for the goblet-cell transcription factors 
FOXA1 and FOXA2 have been described elsewhere 111. Twenty-four hours after 
transfection, the cells were harvested for reporter gene assay. Transfection efficiency was 
determined by parallel detection of pRL-TK activity in a dual luciferase reporter gene 
assay (Promega, Madison, WI, USA). Every single transfection experiment was 
performed in duplicate and was repeated at least 3 times. The AGR2 promoter of the short 
form (NM_006408) from -1542 to -1 was amplified from 100 ng of human genomic DNA 
by polymerase chain reaction (PCR) under standard conditions with the following primers 
(restriction sites underlined) pGL_AGR2_N_sense(XhoI): CGC TCG AGA TCT TTA 
CAG AGG TAA TTA AGT TAA AGT A; pGL_AGR2_N_anti(HindIII): GCA AGC 
TTG TTG CTA ACT CAG AAA CGA ACC TTC CTT TCC CCA A and cloned into the 
pGL3-basic plasmid (Promega). All constructs were sequence-verified with an ABI3700 
sequencer (ABI, Foster City, CA) before use. 
 
Luciferase activity was determined with a dual luciferase reporter gene kit (DLR) from 
Promega according to the manufacturer’s manual. The cells lysates were analyzed with a 
MicroLumatPlus LB96V microplate luminometer (EG&G Berthold, Wellesley, MA) after 
automatic injection of the necessary substrate solutions. All samples were at least 
measured in duplicate. The results for firefly luciferase activity were normalized to renilla 
luciferase activity. 
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2.12 Real-time PCR 
 
 
 
RNA transcript levels were measured using quantitative real-time PCR in 138 patient and 
normal control samples, including 25 normal controls, 56 CD and 57 UC patients. 
Biopsies were obtained from small and large bowel, with 125 of the 138 samples 
originating from the sigmoid colon. Patients included in this study consented to the 
additional research biopsies being taken 24 h prior to endoscopy. The study protocol was 
approved by the hospital ethical committee prior to the start of the study. Total RNA was 
isolated from snap-frozen biopsies using a commercial kit (Qiagen, Hilden, Germany). 
One microgram of total RNA was then reverse-transcribed to cDNA according to the 
manufacturer’s instructions (MultiScribe Reverse Transcriptase, Applied Biosystems, 
Foster City, CA, USA). The cDNA from each sample was diluted 1:5 and arrayed on 384-
well plates for real-time PCR quantitation using an Assays-on-Demand Gene Expression 
Assay for AGR2 (Hs00180702_m1; context sequence: GTT TGT TGA CCC ATC TCT 
GAC AGT T) on the ABI Prism 7900HT Sequence Detection System (Applied 
Biosystems) according to the manufacturer's instructions. Relative transcript levels were 
determined using the standard curve quantitation method and β-actin as the endogenous 
control gene. 
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3. Results 
 
 
3.1 AGR2 and AGR3 genes 
 
 
3.1.1 Mutation detection results 
 
 
The mutation detection experiment identified a total of 30 single nucleotide 
polymorphisms (SNPs), of which nineteen were not previously known. Twenty-five SNPs 
were located in the AGR2 gene and five mapped to the AGR3 gene. One SNP (hcv111845 
– rs4719482) lead to an amino acid exchange in the additional N-terminal sequence of the 
extended splice variant. An overview of all identified SNPs is given in Table 3.1.1a. 
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Table 3.1.1a Results of the mutation detection of all exons and the promoters of the AGR2 
and AGR3 genes. 
Gene Name Position  SNP Type Note 
AGR2 07AGR8N1348 1348 in ncbi exon 8 C/T Intron Novel* 
AGR2 07AGR8N1234 1234 in ncbi exon 8 A/G Intron Novel* 
AGR2 07AGR8N104 1044 in ncbi exon 8 A/C 3’UTR hCV26516309 
AGR2 07AGR8N707 707 in ncbi exon8 A/G 3’UTR Novel* 
AGR2 07AGR8N392 392 in ncbi exon 8 A/T 3’UTR Novel* 
AGR2 hCV1702536 92 in ncbi exon 7 G/T Intron hCV1702536 
AGR2 hcv1702535 46 in ncbi exon 7 C/T Exon  hcv1702535 
AGR2 hCV11830196 -60 before ncbi exon 5 A/T Intron hCV11830196 
AGR2 07AGR1N34 34 in ncbi exon1 A/G 5’UTR hCV8302356 
AGR2 07AGR1N17 17 in ncbi exon1 A/G 5’UTR rs706073 
AGR2 07AGRNP53 -53 before ncbi exon1(in promoter region) A/C Intron hCV27493993 
AGR2 07AGRNP199 -199 before ncbi exon1(in promoter region) C/T Intron hcv1170870 
AGR2 07AGRNP261 -261 before ncbi exon1(in promoter region) C/T Intron rs17136670 
AGR2 07AGRC2_122 -122 before celera exon 2 G/T Intron Novel* 
AGR2 hcv9501480 428 in celera exon 1 A/G Intron hcv9501480 
AGR2 hcv111845 144 in celera exon 1 C/T 5’UTR hcv111845 
AGR2 07AGRCP176 -176 before celera exon 1 (in promoter region) A/G Intron Novel* 
AGR2 07AGRCP197 -197 before celera exon 1 (in promoter region) C/T Intron Novel* 
AGR2 07AGRCP207 -207 before celera exon 1 (in promoter region) C/T Intron Novel* 
AGR2 07AGRCP299 -299 before celera exon 1 (in promoter region) C/T Intron Novel* 
AGR2 07AGR2C395 -395 before celera exon 1 (in promoter region) C/T Intron rs12674158 
AGR2 07AGR2C517 -517 before celera exon 1 (in promoter region) C/T Intron SNP_A-1721592 
AGR2 07AGR2CP574 -574 before celera exon 1 (in promoter region) G/T Intron Novel* 
AGR2 07AGRCP619 -619 before celera exon 1 (in promoter region) A/G Intron Novel* 
AGR2 07AGRCP626 -626 before celera exon 1 (in promoter region) A/G Intron Novel* 
AGR3 hCV11170861 58 in ncbi exon 7 A/G 3’UTR Hcv11170861 
AGR3 07AGR3E6_184 -184 before ncbi exon 6 G/C Intron Novel* 
AGR3 07AGR3E2_89 89 in ncbi exon 2 C/T Intron Novel* 
AGR3 rs4472406 -54 before ncbi exon 2 C/T Intron rs4472406 
AGR3 hCV2571858 290 in ncbi exon 1 A/T Intron hCV2571858 
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3.1.2 Results of Data Analyses 
 
 
The German study cohort and 537 healthy controls of German descent were genotyped for 
30 SNPs of the AGR2 and AGR3 genes. All markers were in Hardy-Weinberg equilibrium 
both in the case and control samples. Case-control and TDT tests of association were 
performed separately for IBD and the sub-phenotypes CD and UC. Results are shown in 
table 3. Markers passing a nominal threshold of p<0.05 in the German screening sample 
were further investigated in an independent patient and control sample from the UK. 
Association statistics in the UK, German and combined cohorts for three diagnostic 
categories (UC, CD, IBD) are presented in Tables 3.1.2a, Table 3.1.2b, Table 3.1.2c and 
Table 3.1.2d.  
 
The consistency of the TDT and case-control statistics and the strength of replication 
between populations were used as a pragmatic guide to judge the trustworthiness of the 
positional signals. The linkage disequilibrium structure (LD) of the human AGR2 and 
AGR3 gene regions is shown in Figure 3.1.2 using the r2 measure of linkage 
disequilibrium. Taking the LD data and the association results (Tables 3.1.2a-3.1.2d) 
together, the association is most consistent in the UC phenotype and localizes to the 5-
prime region of the AGR2 gene (Fig 3.1.2). The association is most pronounced at 
hcv1702494 (combined sample: PTDT=0.011, Pcase/control=0.0007, OR=1.34) and 
hcv111845 (PTDT=0.029, Pcase/control=0.005, OR=1.2837) for the UC phenotype. A 
haplotype analysis including the markers 07AGRNP53, 07AGRNP261, hcv1702494 and 
hcv111845 yielded similar results (German population, UC phenotype, χ2=14.8, df=3, 
p=0.002) with an odds ratio for the risk haplotype of 1.43. In the UK cohort UC 
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phenotype, there was no significance (χ2=8.18, df=4, p=0.085). The association of the CD 
subphenotype to the marker hcv8302351 is largely limited to the German subpopulation. 
Further, TDT and case-control test gave disparate results for this marker.  
 
 
Table 3.1.2a: Overview of single point association statistics in the German cohort. Results 
that meet nominal p-value criterion of 0.05 are highlighted in bold print. 
  IBD CD UC 
Gene SNP TDT Case/control TDT Case/control TDT Case/control 
  P P Allele frequencies P P Allele frequencies P P Allele frequencies 
    cases controls   cases controls   cases controls 
AGR2 hcv1702558 0.61 0.024 0.38 0.33 0.96 0.046 0.38 0.33 0.45 0.11 0.38 0.33 
AGR2 hcv1702545 0.24 0.016 0.37 0.32 0.29 0.035 0.37 0.32 0.58 0.08 0.37 0.33 
AGR2 07AGR8N392 0.24 0.86 0.02 0.02 0.56 0.25 0.02 0.02 0.16 0.26 0.01 0.02 
AGR2 hcv1702537 0.53 0.195 0.22 0.25 0.78 0.26 0.22 0.25 0.48 0.20 0.22 0.25 
AGR2 hcv1702535 0.79 0.27 0.49 0.46 0.89 0.25 0.49 0.46 0.49 0.45 0.48 0.46 
AGR2 hcv8302351 0.016 0.001 0.39 0.47 0.19 0.001 0.39 0.46 0.022 0.018 0.40 0.47 
AGR2 hcv1702532 0.85 0.66 0.19 0.20 0.42 0.87 0.20 0.20 0.41 0.70 0.19 0.20 
AGR2 07AGR1N34 0.2 0.25 0.17 0.19 0.43 0.34 0.17 0.19 0.27 0.24 0.16 0.19 
AGR2 07AGR1N17 0.052 0.299 0.17 0.19 0.11 0.63 0.19 0.19 0.27 0.18 0.16 0.19 
AGR2 07AGRNP53 0.057 0.038 0.21 0.17 0.24 0.11 0.20 0.17 0.11 0.023 0.23 0.18 
AGR2 07AGRNP199 0.07 0.09 0.05 0.07 0.03 0.052 0.05 0.07 0.89 0.38 0.06 0.07 
AGR2 07AGRNP261 0.17 0.12 0.21 0.18 0.52 0.27 0.20 0.18 0.15 0.034 0.23 0.19 
AGR2 hcv1702494 0.013 0.013 0.43 0.48 0.14 0.06 0.44 0.49 0.027 0.01 0.41 0.48 
AGR2 hcv474914 0.18 0.34 0.31 0.33 0.42 0.67 0.32 0.33 0.23 0.06 0.29 0.33 
AGR2 hcv111845 0.028 0.11 0.35 0.38 0.23 0.34 0.36 0.38 0.034 0.03 0.32 0.38 
AGR2 07AGRCP176 0.005 0.078 0.03 0.05 0.029 0.10 0.03 0.05 0.08 0.59 0.04 0.05 
AGR2 07AGRCP197 0.047 0.42 0.11 0.12 0.24 0.86 0.12 0.12 0.06 0.25 0.09 0.11 
AGR2 07AGRCP207 0.21 0.52 0.01 0.001 0.56 0.67 0.001 0.001 0.26 0.14 0.01 0.001 
AGR2 07AGRCP299 0.08 0.097 0.22 0.19 0.33 0.21 0.21 0.19 0.1 0.054 0.24 0.19 
AGR2 07AGR2C395 0.51 0.82 0.14 0.14 0.46 0.76 0.15 0.15 0.92 0.33 0.13 0.15 
AGR2 07AGR2C517 0.56 1 0.14 0.14 0.43 0.54 0.15 0.14 0.92 0.42 0.13 0.14 
AGR2 07AGR2CP574 0.76 0.1 0.01 0.001 0.32 0.1 0.01 0.001 0.16 0.52 0.01 0.001 
AGR2 07AGRCP619 0.12 0.54 0.14 0.13 0.57 0.18 0.16 0.14 0.036 0.66 0.12 0.13 
AGR2 07AGRCP626 0.6 0.7 0.14 0.15 0.67 0.80 0.16 0.15 0.77 0.25 0.13 0.15 
AGR3 hcv318606 0.84 0.92 0.32 0.32 0.96 0.97 0.32 0.32 0.66 0.74 0.33 0.32 
AGR3 hcv11170861 0.68 0.99 0.33 0.33 0.84 0.89 0.32 0.32 0.66 0.84 0.33 0.33 
AGR3 hcv2571858 0.94 0.49 0.29 0.28 0.88 0.71 0.29 0.28 0.73 0.41 0.31 0.29 
AGR3 hcv2571854 0.29 0.72 0.15 0.15 0.95 0.67 0.16 0.15 0.06 0.5 0.16 0.15 
AGR3 hcv2571840 0.42 0.94 0.32 0.32 0.48 0.94 0.33 0.33 0.71 0.96 0.32 0.32 
AGR3 hcv2571839 0.93 0.7 0.31 0.30 0.88 0.87 0.31 0.30 0.94 0.69 0.30 0.29 
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Table 3.1.2b: Replication analysis of significant markers from Table 3 in a UK cohort in 
the UC subgroup. Significant values at the nominal p-value criterion of 0.05 are given in 
bold print. 
 German UK Combined  
SNP TDT Case_control TDT Case_control  TDT Case_control 
 P P Allele frequence P P Allele frequence P P Allele frequence 
   cases controls   cases controls   cases controls 
hcv1702558 0.45 0.11 0.38 0.33 0.41 0.39 0.39 0.36 0.29 0.07 0.38 0.34 
hcv1702545 0.58 0.08 0.37 0.33 0.11 0.35 0.38 0.34 0.24 0.04 0.38 0.33 
hcv8302351 0.022 0.018 0.40 0.47 0.91 0.86 0.40 0.41 0.04 0.04 0.40 0.44 
07AGRNP53 0.11 0.023 0.23 0.18 0.39 0.51 0.13 0.21 0.69 0.013 0.23 0.19 
07AGRNP199 0.89 0.38 0.06 0.07 0.39 0.27 0.05 0.07 0.72 0.21 0.06 0.07 
07AGRNP261 0.15 0.034 0.23 0.19 0.33 0.497 0.22 0.21 0.84 0.023 0.23 0.19 
hcv1702494 0.027 0.01 0.41 0.48 0.17 0.045 0.39 0.45 0.011 0.0007 0.39 0.47 
hcv111845 0.034 0.03 0.32 0.38 0.41 0.031 0.33 0.39 0.029 0.005 0.33 0.38 
07AGRCP176 0.08 0.59 0.04 0.05 0.80 0.88 0.05 0.05 0.14 0.63 0.04 0.05 
07AGRCP197 0.06 0.25 0.09 0.11 0.22 0.80 0.12 0.12 0.03 0.31 0.11 0.12 
07AGRCP619 0.036 0.66 0.12 0.13 0.15 0.71 0.14 0.13 0.01 0.91 0.13 0.13 
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Table 3.1.2c: Replication analysis of significant markers from Table 3 in a UK cohort in 
the CD subgroup. Significant values at the nominal p-value criterion of 0.05 are given in 
bold print. 
 German UK Combined  
SNP TDT Case_control TDT Case_control  TDT    
 P P Allele frequence P P Allele frequence P P Allele frequence 
   cases controls   cases controls   cases controls 
hcv1702558 0.96 0.46 0.38 0.33 0.87 0.21 0.60 0.65 0.38 0.024 0.38 0.34 
hcv1702545 0.29 0.035 0.37 0.32 0.21 0.20 0.39 0.34 0.13 0.018 0.38 0.45 
hcv8302351 0.19 0.001 0.39 0.46 0.10 0.22 0.38 0.42 0.49 0.0001 0.38 0.45 
07AGRNP53 0.24 0.11 0.20 0.17 0.49 0.17 0.17 0.21 0.22 0.50 0.19 0.18 
07AGRNP199 0.03 0.052 0.05 0.07 0.24 0.06 0.05 0.07 0.014 0.013 0.05 0.07 
07AGRNP261 0.52 0.27 0.20 0.18 0.66 0.17 0.17 0.21 0.53 0.8 0.19 0.19 
hcv1702494 0.14 0.06 0.44 0.49 0.04 0.23 0.41 0.45 0.028 0.038 0.44 0.48 
hcv111845 0.23 0.34 0.36 0.38 0.10 0.29 0.35 0.38 0.14 0.18 0.36 0.38 
07AGRCP176 0.029 0.10 0.03 0.05 0.72 0.7 0.05 0.05 0.11 0.26 0.04 0.05 
07AGRCP197 0.24 0.86 0.12 0.12 0.44 0.5 0.11 0.13 0.12 0.65 0.12 0.12 
07AGRCP619 0.57 0.18 0.16 0.14 0.22 0.64 0.13 0.12 0.45 0.15 0.15 0.13 
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Table 3.1.2d: Replication analysis of significant markers from Table 3 in the UK cohort in 
for the joint IBD phenotype. Significant values at the nominal p-value criterion of 0.05 
are given in bold print. 
 German UK Combined  
SNP TDT Case_control TDT Case_control  TDT    
 P P Allele frequence P P Allele frequence P P Allele frequence 
   cases controls   cases controls   cases controls 
hcv1702558 0.61 0.024 0.38 0.33 0.06 0.31 0.61 0.64 0.18 0.03 0.38 0.34 
hcv1702545 0.24 0.016 0.37 0.32 0.14 0.25 0.38 0.34 0.054 0.016 0.37 0.33 
hcv8302351 0.016 0.001 0.39 0.47 0.17 0.51 0.39 0.41 0.005 0.005 0.39 0.41 
07AGRNP53 0.057 0.038 0.21 0.17 0.28 0.7 0.20 0.21 0.037 0.13 0.21 0.18 
07AGRNP199 0.07 0.09 0.05 0.07 0.77 0.16 0.05 0.07 0.08 0.06 0.05 0.07 
07AGRNP261 0.17 0.12 0.21 0.18 0.34 0.73 0.20 0.21 0.12 0.23 0.21 0.19 
hcv1702494 0.013 0.013 0.43 0.48 0.015 0.11 0.41 0.45 0.001 0.006 0.42 0.47 
hcv111845 0.028 0.11 0.35 0.38 0.26 0.013 0.34 0.39 0.012 0.04 0.35 0.38 
07AGRCP176 0.005 0.078 0.03 0.05 0.88 0.97 0.05 0.05 0.031 0.20 0.04 0.05 
07AGRCP197 0.047 0.42 0.11 0.12 0.17 0.61 0.12 0.13 0.013 0.35 0.11 0.12 
07AGRCP619 0.12 0.54 0.14 0.13 0.55 0.77 0.13 0.13 0.03 0.5 0.14 0.13 
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Fig 3.1.2 Overview of the linkage disequilibrium structure of the human AGR2 and AGR3 
region. The panels A and D show the physical map and the exon-intron structure of the 
AGR2 gene. The panel B shows the r2 plot for the region. The level of LD is highlighted 
in color (red r2=1, light blue r2=0). The association results for the UC phenotype in the 
combined German / UK cohort are given in panel C. 
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3.1.3 cDNA amplification results 
 
 
The gene model of AGR2 was evaluated using RT-PCR in a tissue panel designed on the 
basis of the NCBI and Celera gene models. The presence of the additional 5’ exon 
predicted in the Celera database was confirmed. The two different transcripts also show a 
significantly different expression pattern (Fig 3.1.3). The extended form shows a 
predominant expression in the prostate whereas the shorter form shows a ubiquitous 
expression pattern. The resultant gene model has been submitted to Genbank. 
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Fig 3.1.3 Evaluation of the expression pattern of the two AGR2 splice variants. 
RT-PCR was performed in the Human Multiple Tissue Panels using the 
primers given in the methods. 
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3.1.4 Real-time PCR results 
 
 
The relative expression of total AGR2 was quantified by real-time PCR in 25 normal 
controls, 56 CD and 57 UC patients. Median expression levels (arbitrary normalization 
units) of 1.07 for normal controls, 0.57 for CD and 0.67 for UC were observed. This 
expression difference was statistically significant as tested by non-parametric testing 
(p=0.0000001 for CD versus NC and p=0.0000001 for UC versus NC; Mann Whitney U 
Test, Fig 3.1.4).  
 
For 91 IBD biopsies, genotype data for the AGR markers was available. Individuals, who 
were homozygous for the risk allele at marker hcv111845, showed an overall lower 
expression relative expression level than the remainder of the samples (relative expression 
level 0.63 for “22” genotype versus 0.71). However, this difference was not statistically 
significant due to the limited sample number (p>0.1).  
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3.1.5 Expression of Reporter gene construct 
 
 
A luciferase reporter gene construct (pGL3B-AGR2 [-1542]) driven by the AGR2 
promoter was transfected into HEK 293 cells. Co-transfection of the forkhead box 
transcription factors FOXA1 and FOXA2, which have been implicated in maintaining 
goblet cell function 112, led to a significantly increased luciferase activity (Fig 3.1.5). 
Median luciferase activities (out of seven replicates) of 1023 for the control and 3378 and 
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Fig 3.1.4 Relative expression of AGR2 in normal and IBD patient samples. The 
relative expression of AGR2 was quantitated by real-time PCR in 25 normal 
controls, 56 CD and 57 UC patients. The expression of AGR2 is significantly 
different between normal controls and either CD or UC samples (p-value <0.001, as 
shown by Mann Whitney U Test). * = Median 
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2455 for the FOXA1 and FOXA2 co-transfection experiments were observed (p<0.001, 
Mann-Whitney U-test).   
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Fig 3.1.5 Luciferase activity observed after stimulation with FoxA1 and 
FoxA2. (-): transfected with pGL3B-AGR2[-1542] without stimulation; 
FoxA1: co-transfected with pGL3B-AGR2 [-1542] and FoxA1 gene; FoxA2: 
transfected with pGL3B-AGR2 [-1542] and FoxA2 gene. 
 
 
3.2 Association mapping on chromosome 12 
 
 
 
3.2.1 Identification of the association lead on chromosome 12 
 
 
For the association study of inflammatory bowel disease (IBD) susceptibility genes, we 
selected 15 SNPs covered 62.6-63.2Mb region on chromosome 12q. All of the 15 SNPs 
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were genotyped in a German cohort, which contained 776 trios with IBD (484 with CD, 
292 with UC).  All markers were in Hardy-Weinberg equilibrium both in the case and 
control samples. Case-control and TDT tests of association were performed for IBD and 
the sub-phenotypes CD and UC. Results are shown in table 3.2.1  
 
Table 3.2.1: Overview of single point association statistics in the German cohort. 
 IBD CD UC 
SNP TDT Case/control TDT Case/control TDT Case/control 
 P P Allele 
frequencies 
P P Allele frequencies P P Allele frequencies 
   cases controls   cases controls   cases controls 
hcv1521134 0.62 0.82 0.19 0.19 0.32 0.99 0.19 0.19 0.75 0.60 0.20 0.19 
hcv2690436 0.23 0.68 0.23 0.23 0.67 0.57 0.22 0.23 0.19 0.93 0.24 0.24 
hcv2690456 0.32 0.46 0.28 0.26 0.90 0.44 0.28 0.27 0.18 0.65 0.27 0.26 
hcv1403210 0.41 0.69 0.50 0.50 0.86 0.38 0.48 0.50 0.32 0.66 0.48 0.50 
hcv8757697 0.97 0.94 0.48 0.50 0.90 0.98 0.49 0.50 0.95 0.86 0.48 0.49 
hcv8757644 0.44 0.19 0.25 0.28 0.51 0.99 0.28 0.29 0.06 0.003 0.21 0.28 
hcv2630409 0.66 0.09 0.37 0.33 0.44 0.25 0.36 0.32 0.84 0.04 0.39 0.34 
hcv11290387 0.37 0.40 0.22 0.21 0.76 0.86 0.20 0.20 0.12 0.036 0.25 0.20 
hcv11290388 0.24 0.35 0.22 0.21 0.76 0.94 0.20 0.21 0.055 0.034 0.25 0.21 
hcv9277491 0.42 0.31 0.22 0.21 0.94 0.98 0.20 0.20 0.24 0.03 0.25 0.20 
hcv400963 0.44 0.02 0.40 0.44 0.51 0.27 0.42 0.46 0.076 0.0008 0.35 0.44 
hcv12069598 0.81 0.43 0.14 0.12 0.45 0.82 0.13 0.12 0.67 0.19 0.15 0.12 
hcv491186 0.55 0.39 0.25 0.25 0.72 0.37 0.25 0.25 0.63 0.60 0.25 0.26 
hcv22272931 0.69 0.67 0.24 0.25 0.89 0.88 0.25 0.25 0.67 0.46 0.23 0.25 
hcv315870 0.40 0.49 0.45 0.43 0.24 0.35 0.46 0.42 1 0.92 0.44 0.43 
 
Two SNPs (hcv8757644 & hcv400963) show highly significant association (p<0.005) 
with UC sub-group in case-control analyses. 
 
3.2.2 High density SNP mapping in the association region 
 
 
 
Further investigation of this region comprised genotyping 35 additional markers in the 
same samples. These markers were marked as tagging SNPs in HapMap 
(www.hapmap.org). All markers were in Hardy-Weinberg equilibrium both in the case 
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and control samples. For the analysis of association in the case control, the population 
was classified into the diagnostic categories healthy and affected with IBD, which 
included CD and UC. Cases for each category were taken from the trios and single 
patients. Pearson’s χ2 were calculated. The results were shown in Fig 3.2.2a. The most 
significant SNP was rs7955726, which yielded a p-value of 0.0006. 
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Fig 3.2.2a  Pearson’s χ2 in case-control studies. Significance of a peak at 
the 95% confidence interval is reached at value of 3.9 with 1 df.  
 
Besides the case control study, the association to disease was tested using family-based 
transmission distortion. In Genehunter program (version 2.1) the number of alleles 
transmitted from parent to offspring was compared to the number of untransmitted alleles 
81. The significance of the association was calculated using χ2 test and the p-value at a 
95% confidence interval. The results of the single point association with transmission are 
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shown in Fig 3.2.2b. The highest significant SNP marker was also rs7955726, which gave 
p-value at 0.002. 
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 Fig 3.2.2b  Pearson’s χ2 in case-control studies. Significance of a peak at 
the 95% confidence interval is reached at value of 3.9 with 1 df.  
 
Different associations can be identified for each disease category. There is one peak of 
strong association with UC in case-control studies and TDT that reach a significance level 
of p<0.05. Several markers and resulting peak were mostly carried through UC group. In 
IBD category, a weak association also can be seen in the same peak. There was no peak of 
association with CD category. The most significant SNP, rs7955726, showed strong 
association with UC category both in case-control studies and TDT. The overview is 
shown in table 3.2.2. The most significant SNP was located in LOC115749 gene. 
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Table3.2.2 Overview of single point association statistics in the German cohort 
 IBD CD UC 
SNP TDT Case/control TDT Case/control TDT Case/control 
 P P Allele 
frequencies 
P P Allele frequencies P P Allele frequencies 
     cases controls   cases controls   cases controls 
rs7311377 0.434 0.709 0.43 0.44 0.138 0.211 0.41 0.45 0.522 0.475 0.46 0.44 
rs1456046 0.922 0.706 0.39 0.38 0.527 0.899 0.39 0.39 0.535 0.634 0.40 0.38 
rs10878102 0.886 0.596 0.36 0.35 0.755 0.742 0.36 0.35 0.553 0.572 0.36 0.34 
rs1827073 0.874 0.218 0.10 0.08 0.666 0.681 0.08 0.08 0.480 0.047 0.11 0.08 
rs2279666 0.819 0.491 0.47 0.46 1 0.774 0.47 0.46 0.718 0.371 0.48 0.46 
rs4763138 0.680 0.530 0.48 0.46 0.811 0.844 0.47 0.46 0.720 0.376 0.49 0.46 
rs789722 0.774 0.554 0.47 0.48 0.952 0.984 0.49 0.48 0.576 0.265 0.45 0.49 
rs1146122 0.890 0.830 0.48 0.49 0.681 0.746 0.50 0.49 0.766 0.395 0.47 0.49 
rs10748002 1 0.623 0.47 0.48 0.498 0.815 0.48 0.48 0.421 0.610 0.47 0.48 
rs10878111 0.963 0.711 0.47 .048 0.423 0.922 0.48 0.49 0.394 0.645 0.47 0.48 
rs1695105 0.963 0.791 0.48 0.50 0.757 0.570 0.47 0.50 0.775 0.814 0.49 0.49 
rs790008 0.954 0.056 0.20 0.25 0.408 0.281 0.22 0.26 0.289 0.028 0.19 0.24 
rs1464055 0.368 0.468 0.45 0.48 0.665 0.531 0.45 0.48 0.376 0.585 0.45 0.47 
rs11175286 0.957 0.055 0.24 0.28 0.530 0.511 0.26 0.29 0.490 0.005 0.21 0.27 
hcv2690409 0.787 0.075 0.38 0.33 0.671 0.230 0.37 0.32 0.946 0.039 0.39 0.34 
rs1657050 1 0.048 0.24 0.28 0.526 0.539 0.26 0.29 0.439 0.003 0.20 0.27 
rs1162974 0.234 0.402 0.22 0.22 0.746 0.677 0.19 0.21 0.035 0.038 0.25 0.21 
rs7954838 0.170 0.463 0.22 0.22 1 0.526 0.19 0.21 0.044 0.034 0.26 0.21 
rs7955726 0.029 0.034 0.32 0.29 0.838 0.603 0.28 0.28 0.002 0.0006 0.36 0.28 
rs2164504 0.395 0.016 0.40 0.46 0.902 0.253 0.43 0.47 0.140 0.0016 0.37 0.45 
rs6421214 0.731 0.550 0.45 0.43 0.213 0.207 0.47 0.43 0.374 0.768 0.42 0.43 
rs10878167 0.488 0.048 0.21 0.25 0.391 0.252 0.22 0.25 1 0.015 0.19 0.25 
rs11175383 0.914 0.361 0.26 0.24 0.521 0.652 0.25 0.24 0.361 0.191 0.28 0.24 
rs10784408 0.683 0.649 0.14 0.13 0.857 0.855 0.14 0.13 0.677 0.450 0.15 0.13 
rs7976457 0.938 0.337 0.11 0.13 0.361 0.876 0.12 0.13 0.325 0.087 0.09 0.12 
rs1317532 0.143 0.432 0.48 0.46 0.159 0.379 0.48 0.47 0.551 0.758 0.47 0.46 
rs1317535 0.101 0.535 0.32 0.34 0.091 0.632 0.32 0.34 0.590 0.653 0.32 0.34 
rs6581575 0.639 0.213 0.48 0.45 0.903 0.389 0.47 0.46 0.379 0.192 0.49 0.45 
rs7972780 0.638 0.395 0.50 0.47 0.668 0.542 0.49 0.48 0.211 0.390 0.50 0.47 
rs4964110 0.334 0.262 0.09 0.10 0.249 0.274 0.09 0.10 0.900 0.420 0.09 0.10 
rs10506538 0.824 0.189 0.11 0.09 0.283 0.491 0.10 0.09 0.359 0.084 0.12 0.09 
rs7963840 1 0.917 0.37 0.38 0.950 0.965 0.38 0.38 0.940 0.787 0.37 0.37 
rs1245035 0.229 0.890 0.40 0.40 0.479 0.482 0.41 0.40 0.310 0.554 0.38 0.40 
rs1520765 0.448 0.871 0.47 0.46 0.616 0.402 0.49 0.47 0.562 0.513 0.45 0.46 
rs1619280 1 0.998 0.46 0.47 0.808 0.393 0.44 0.46 0.777 0.320 0.49 0.46 
 
 
 
3.2.3 Analyses of LD in the association region 
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Linkage disequilibrium (LD) is the condition in which the haplotype frequencies in a 
population deviate from the values they would have if the genes at each locus were 
combined at random. When there is no such deviation, when linkage disequilibrium equal 
to zero, then the population is said to be in linkage equilibrium. Linkage Disequilibrium 
(LD) arises as a consequence of three features of life a) the physical structure of 
chromosomes; b) the inherent mutations that occur at random during DNA replication; c) 
the rate of recombination between any two given loci. Taking each in turn this means that 
markers, which are after all simply mutations, be it SNPs where one base pair has 
changed or micro-satellites (where replication slippage has occured), do not undergo 
independent assortment if they are on the same chromosome. This means that when a new 
mutation arises it will be inherited along with all of the other markers/polymorphisms that 
occur on that chromosome, unless of course a recombination event occurs between two 
loci that serve to break the pattern of mutations that are inherited on one chromosome. 
There are two major parameters, one is D’ and another is r2. D' is scaled version of D 
(Equivalent to the co-variance between loci) constrainted to lie between 0 and 1. The 
higher the value is, the stronger LD is. The r2 is the gametic correlation coefficient. 
 
Due to linkage disequilibrium between genes, a distortion of the true location of a 
susceptibility gene is likely. Therefore, pair-wise LD analysis in the control population 
was performed on the set of markers employed for the screening experiment. Markers 
with a higher frequency than 1% were included into analysis of LD structure in this study. 
D’ values were calculated for all pair-wise inferred two-locus haplotypes for the 49 SNPs. 
D’ values greater than 0.5 were considered as evidence of linkage disequilibrium between 
markers 113 (Fig 3.2.3). In the analyzed fragment, four blocks were discovered. The 
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strongest LD was observed between markers in the third region, which was located 
between rs1162974 and rs7955726. This region includes LOC115749 gene. This region 
also demonstrated significant results in the case-control studies and TDT analysis. 
 
 
 
 
 
 
 
 
 
 
 
LD block1
LD block3
LD block2
LD block4
Fig 3.2.3 LD between 49 SNPs markers typed for association on chromosome 12. 
The colored squares code D’ value. LD values marked in with red indicate LD 
values higher than 0.5. 
 
 
 
3.2.4 Candidate gene analyses in association region 
 
3.2.4.1 Mutation detection results 
 
 
We selected three candidate genes in this region, namely LOC115749, FLJ32549 and 
BC042855. In total, 20 SNPs were identified in the mutation detection experiment. One 
SNP in LOC115749 gene (BC03_SNP2) located in exon, which was a synonymous 
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mutation, and one SNP in FLJ32549 gene (12BC036N2232) lead to an amino acid 
exchange from asparagine to serine. Two deletions (12BC039N8134, 12BC036N4343) 
and one insertion (12BC04N326) were found in those three genes (Table 3.2.4.1).  All the 
other SNPs were located in the intron of these three genes. 
 
Table 3.2.4.1 Results of the mutation detection of the LOC115749, BC042855 and 
FLJ32549 genes. 
Gene Name Position  SNP Type Note 
LOC115749 BC03_SNP1 -347 before exon 1 C/T Intron  
LOC115749 BC039_SNP3 -74 before exon 4 A/C Intron  
LOC115749 rs12582530 -23 before exon 5 C/G Intron  
LOC115749 rs12581950 118 in exon 6 C/T Intron  
LOC115749 rs10878132 -118 before exon 8 G/T Intron   
LOC115749 BC03_SNP2 63 in exon 8 G/T Exon Synonymous 
LOC115749 12BC039N8134 134 in exon 8 A/- Intron  One A deletion 
LOC115749 rs2010889 -193 before exon 9 C/T Intron  
LOC115749 rs2010893 -136 before exon 9 C/T Intron  
LOC115749 rs6581534 97 in exon 9 A/C Intron  
BC042855 12BC04N1192 192 in exon 1 C/T Intron  
BC042855 12BC04N338 -38 before exon 3 A/G Intron  
BC042855 12BC04N326 -26 before exon 3 -/T Intron One T insertion 
BC042855 rs7489144 365 in exon 5 C/T Exon  
FLJ32549 12BC036N2232 232 in exon 2 A/G Exon Asn to Ser 
FLJ32549 12BC036N31123 1123 in exon 3 T/- 3’UTR One T deletion 
FLJ32549 BC036_SNP2 343 in exon 4 A/G 3’ UTR  
FLJ32549 rs2643665 449 in exon 4 A/G 3’UTR  
FLJ32549 12BC036N4553 553 in exon 4 A/G 3’UTR  
FLJ32549 rs1133242 1235 in exon 4 C/T 3’UTR  
 
 
3.2.4.2 Statistical analyses results 
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Ten SNPs from the mutation detection in these three genes were genotyped. Two of them 
were significant in case-control studies in the UC subgroup. One of the SNPs, 
BC03_SNP2, was located in exon 8 and didn’t cause amino acid change. The other 
significant was intronic. Three markers showed significant results in TDT. Two of them 
(rs6581534 and BC039_SNP3), which were intronic SNPs, were located within the 
LOC115749 gene. The third one (rs7489144) was located within BC042855 gene. The 
overview is shown in table 3.2.4.2. 
 
Table 3.2.4.2  Overview of single point association statistics in the German cohort. 
Results that meet nominal p-value criterion of 0.05 are highlighted in bold print 
  IBD CD UC 
Gene SNP TDT Case/control TDT Case/control TDT Case/control 
  P P Allele 
frequencies 
P P Allele frequencies P P Allele frequencies 
    cases controls   cases controls   cases controls 
FLJ32549 rs1133242 0.693 0.121 0.21 0.24 0.605 0.412 0.22 0.25 0.223 0.066 0.19 0.23 
FLJ32549 rs2643665 1 0.977 0.49 0.50 0.616 0.858 0.49 0.50 0.560 0.831 0.50 0.50 
FLJ32549 BC036_SNP2 0.366 0.621 0.01 0.01 0.317 0.887 0.01 0.01 1 0.321 0.003 0.01 
LOC115749 rs6581534 0.184 0.540 0.22 0.22 1 0.607 0.19 0.21 0.048 0.071 0.25 0.21 
LOC115749 rs2010893 0.312 0.445 0.22 0.22 0.690 0.658 0.19 0.21 0.050 0.047 0.25 0.21 
LOC115749 rs2010889 0.342 0.517 0.22 0.22 0.629 0.587 0.19 0.21 0.054 0.059 0.25 0.21 
LOC115749 BC03_SNP2 0.347 0.400 0.22 0.21 0.936 0.726 0.20 0.21 0.172 0.025 0.26 0.21 
LOC115749 BC039_SNP3 0.176 0.837 0.22 0.23 1 0.449 0.20 0.22 0.043 0.175 0.25 0.22 
LOC115749 BC03_SNP1 0.694 0.497 0.43 0.42 0.546 0.343 0.44 0.41 0.950 0.932 0.42 0.42 
BC042855 rs7489144 0.921 0.156 0.06 0.04 0.043 0.025 0.08 0.04 0.039 0.916 0.05 0.04 
 
 
3.2.4.3 cDNA amplification results 
 
 
The gene model of LOC115749 gene, BC042855 gene and FLJ32549 gene were 
evaluated using RT-PCR in a tissue panel designed on the basis of the NCBI gene models. 
The LOC115749 gene was highly expressed in testis and also expressed in kidney, 
prostate, placenta and thymus. Two splicing variants were seen in kidney, prostate, 
placenta and thymus (Fig 3.2.4.3a). The FLJ32549 gene was expressed in all tissues. 
 Results 85
BC042855 gene was expressed only in muscle, heart and brain. BC042855 gene has two 
different variants expressed in brain (Fig 3.2.4.3b). 
 
 
 
 
 
 
 
 
 
Fig 3.4.2.3a Evaluation of the expression pattern of the LOC115749 gene. RT-
PCR was performed in the Human Multiple Tissue Panels using the primers given 
in the methods. 
 
 
 
Fig 3.2.4.3b Evaluation of the expression pattern of the BC042855 and 
BC036246 gene. RT-PCR was performed in the Human Multiple Tissue 
Panels using the primers given in the methods. 
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3.2.4.4 Rapid amplification of cDNA ends (RACE) results 
 
 
 
Five prime rapid amplification of cDNA ends (RACE) was performed in kidney cDNA to 
evaluate the gene model of 5’ end of the LOC115749 gene. Two transcripts were found in 
the experiment, and no new 5’ end exons were found according to the NCBI database (Fig 
3.2.4.4). This result confirmed the gene model that already exists in the NCBI database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.2.4.4 RACE results of the BC039369 gene. The RACE products obtained from kidney 
tissue are consistent with the gene model in the NCBI database. 
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4. Discussion 
 
 
4.1 AGR2 gene 
 
 
In Xenopus, XAG2 has been shown to act as a signaling molecule and plays an important 
role in cement gland differentiation and ectodermal patterning 74. XAG2 is highly expressed 
in the cement gland, which consists of mucus-secreting cells functioning as endocrine 
organs. Over-expression of XAG2 induces both cement gland differentiation and expression 
of other anterior neural marker genes 74. The AGR2 gene is the human homologue of the 
Xenopus laevis cement gland gene XAG, mapping to chromosome band 7p21.3 114. This 
gene is highly expressed in the trachea, lung, stomach, colon, prostate and small intestine 76. 
In Xenopus laevis, the XAG families of genes are expressed in a gradient in the ectoderm 
during early development of the cement gland, and appear to be important factors during 
differentiation of this organ 115. The cement gland arises from the outer layer of embryonic 
ectoderm and forms a cone of columnar epithelium. AGR2 has been found to be expressed 
in tissues that contain mucous secreting cells and/or function as endocrine organs. Thus, 
from an evolutionary perspective, the human AGR genes may be involved in the epithelial 
barrier function.  
 
Goblet cells reside throughout the length of the small and large intestine and are responsible 
for the production and maintenance of the protective mucus blanket by synthesizing and 
secreting high-molecular-weight glycoproteins known as mucins. Mucus is secreted by the 
epithelial surfaces throughout the gastrointestinal tract from the stomach to the colon. It 
forms a gel adherent to the surface that provides a protective barrier between the underlying 
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epithelium and the lumen. The mucus layer provides a protective barrier against pathogens 
by acting as a physical barrier, since the mucus layer provides binding sites for the bacterial 
adhesions. At the same time in the colon, the mucus layer provides an essential environment 
for the enteric microflora 116.  The involvement of goblet cell mucins in the 
pathophysiology of intestinal neoplasia and ulcerative colitis are presented 64. 
 
Foxa transcription factors comprise a subfamily of forkhead transcription factors. The so-
called forkhead box encodes a winged-helix DNA-binding motif, the name of which 
describes the structure of the domain when bound to DNA. The three Fox (forkhead box) 
group A genes, Foxa1, Foxa2 and Foxa3, are expressed in embryonic endoderm, the germ 
layer that gives rise to the digestive system. The Fox group A genes also contribute to the 
specification of the pancreas and the regulation of glucose homoeostasis. The 
transactivation domains in the C-terminal and N-terminal regions of Foxa1 and Foxa2 share 
structural similarity 117 118. In mouse, Foxa2 is expressed first in the primitive streak at E6.5, 
shortly after the onset of gastrulation 119. Thereafter it is expressed in the notochord, gut 
endoderm and ventral midline of the central nervous system. Later in embryonic 
development, Foxa2 is expressed in endodermally derived tissues including liver, lung, 
pancreas and intestine 120 121. Foxa2 is an important regulator and deletion of the Foxa2 
gene in pancreatic beta-cells in mice results in a phenotype resembling PHHI (persistent 
hyperinsulinaemic hypoglycaemia of infancy) 122. Foxa1 was shown to be an essential 
activator of glucagon gene expression in vivo 123.  
 
The hypothesis of involvement of the AGR2 gene in epithelial barrier function is further 
supported by the regulation of the AGR2 promoter by transcription factors typical for 
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epithelial goblet cells. Luciferase reporter gene assays show an activation of human AGR2 
promoter by FOXA1 and FOXA2. FOXA1 contributes to pancreatic beta-cell function 124 
and both regulate signaling and transcriptional programs required for morphogenesis and 
goblet cell differentiation during formation 112 125. There is a binding site for Hepatic 
Nuclear Factor 1(HNF1) in the AGR2 promoter region at SNP 07AGRNP53. HNF1 and 
FOXA1 and FOXA2 belong to the same family. 
 
We observed association of markers in the 5’ region of AGR2 primarily with the UC 
phenotype in two independent cohorts (UK and German extraction). All four significant 
SNPs were located in 5’ end of the AGR2 gene (Table 2). Additionally, 07AGRNP53 and 
07AGRNP261, which are part of the risk haplotype, were located in promoter region. The 
expression level of AGR2 in UC patients was significantly lower than in healthy controls. 
Also, a trend towards lower expression of AGR2 in carriers of the risk alleles was observed. 
The link between down-regulation of the AGR2 transcript in risk allele carriers and in 
disease has not yet fully been explored. None of the individual promoter SNPs identified in 
this study (Table 2) fully defined the disease haplotype, but also the more distant markers 
hcv1702494 and hcv111845 are needed for the definition of the risk haplotype. This 
suggests that further, unidentified private mutations contribute to the down-regulation of 
AGR2 in disease. 
 
4.2 Chromosome 12 
 
 
4.2.1 Association mapping 
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Association mapping employing diallelic SNP markers was performed in the linkage region 
on chromosome 12q. In the beginning, 15 SNP markers within this region were genotyped 
in a German cohort, which included 776 trios with IBD (484 with CD, 292 with UC) and 
360 unrelated healthy control individuals. The SNP markers were tested for allele and 
genotype association with the disease phenotypes IBD, CD and UC in a case-control study 
and a TDT association. Two SNP markers showed association with UC subgroup in the 
case-control study. However, none of markers was significant in the TDT association study. 
The two markers were hcv8757644 (PTDT=0.088; Pcase/control=0.0036) and hcv400963 
(PTDT=0.076; Pcase/control=0.00057). For the SNP hcv8757644, no significant signal was seen 
in IBD and CD population. For the SNP hcv400963, no significant result was seen in CD 
subgroup and a weak significant result was seen in IBD population (PTDT=0.44; 
Pcase/control=0.02). These results showed that this region associated with UC subgroup.  
 
For further study, an additional 35 SNP markers were selected within this region. The 
selected SNP markers covered the entire LD block in this region, and all SNPs were tagging 
SNPs according to the HapMap website (www.hapmap.org). The selected SNP markers 
were genotyped in the German cohort described above. Together with the 15 SNP markers 
that were described above, an overview of the whole region was obtained (Table 4.2.1, Fig 
4.2.1a, Fig 4.2.1b). Two association leads were observed in case-control studies in UC 
subgroup. One lead was located between marker rs7955726 (Pcase/control=0.00068) and 
marker hcv400963 (Pcase/control=0.00056). This region was located around the LOC115749 
gene. Another lead was located between marker rs1657050 (Pcase/control=0.0034) and marker 
hcv8757644 (Pcase/control=0.0036). FLJ32549 gene was located around this region.   
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One association peak was found in TDT studies in UC subgroup. This peak was located at 
marker rs7955726 (PTDT=0.00229). This is the same marker that showed significance in the 
case-control studies, located around LOC115749 gene. The overlap of the association 
results gave a good indication toward the potential location of a disease gene. By examining 
the LD between physically close markers, association to a disease-causing mutation could 
be identified through an SNP that is located nearby if it is positioned on the same haplotype.  
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Table 4.2.1 Overview of single point association statistics in the German cohort. Results 
that meet nominal p-value criterion of 0.05 are highlighted in bold print. 
 IBD CD UC 
SNP TDT Case/control TDT Case/control TDT Case/control 
 P P Allele 
frequencies 
P P Allele frequencies P P Allele frequencies 
   cases controls   cases controls   cases controls 
rs7311377 0.434 0.709 0.43 0.44 0.138 0.211 0.41 0.45 0.522 0.475 0.46 0.44 
rs1456046 0.922 0.706 0.39 0.38 0.527 0.899 0.39 0.39 0.535 0.634 0.40 0.38 
rs10878102 0.886 0.596 0.36 0.35 0.755 0.742 0.36 0.35 0.553 0.572 0.36 0.34 
rs1827073 0.874 0.218 0.10 0.08 0.666 0.681 0.08 0.08 0.480 0.047 0.11 0.08 
hCV1521134 0.398 0.797 0.19 0.19 0.080 0.861 0.19 0.19 0.576 0.798 0.19 0.19 
rs2279666 0.819 0.491 0.47 0.46 1 0.774 0.47 0.46 0.718 0.371 0.48 0.46 
rs4763138 0.680 0.530 0.48 0.46 0.811 0.844 0.47 0.46 0.720 0.376 0.49 0.46 
rs789722 0.774 0.554 0.47 0.48 0.952 0.984 0.49 0.48 0.576 0.265 0.45 0.49 
hCV2690436 0.282 0.670 0.23 0.24 0.827 0.652 0.23 0.23 0.194 0.788 0.23 0.24 
rs1146122 0.890 0.830 0.48 0.49 0.681 0.746 0.50 0.49 0.766 0.395 0.47 0.49 
hCV2690456 0.292 0.344 0.28 0.26 0.947 0.400 0.28 0.27 0.144 0.430 0.28 0.26 
rs10748002 1 0.623 0.47 0.48 0.498 0.815 0.48 0.48 0.421 0.610 0.47 0.48 
rs10878111 0.963 0.711 0.47 .048 0.423 0.922 0.48 0.49 0.394 0.645 0.47 0.48 
hCV1403120 0.358 0.709 0.50 0.50 0.662 0.407 0.48 0.50 0.391 0.715 0.48 0.50 
BC036_SNP2 0.366 0.621 0.01 0.01 0.317 0.887 0.01 0.01 1 0.321 0.003 0.01 
hcv8757697 0.930 0.882 0.48 0.50 0.799 0.885 0.48 0.50 0.903 0.913 0.48 0.49 
rs1695105 0.963 0.791 0.48 0.50 0.757 0.570 0.47 0.50 0.775 0.814 0.49 0.49 
rs790008 0.954 0.056 0.20 0.25 0.408 0.281 0.22 0.26 0.289 0.028 0.19 0.24 
hcv8757644 0.351 0.188 0.25 0.28 0.734 0.942 0.28 0.29 0.088 0.0036 0.21 0.28 
rs1464055 0.368 0.468 0.45 0.48 0.665 0.531 0.45 0.48 0.376 0.585 0.45 0.47 
rs11175286 0.957 0.055 0.24 0.28 0.530 0.511 0.26 0.29 0.490 0.005 0.21 0.27 
hcv2690409 0.787 0.075 0.38 0.33 0.671 0.230 0.37 0.32 0.946 0.039 0.39 0.34 
rs1657050 1 0.048 0.24 0.28 0.526 0.539 0.26 0.29 0.439 0.003 0.20 0.27 
rs1162974 0.234 0.402 0.22 0.22 0.746 0.677 0.19 0.21 0.035 0.038 0.25 0.21 
hcv11290387 0.390 0.430 0.22 0.21 0.576 0.687 0.19 0.20 0.094 0.03 0.25 0.21 
hcv11290388 0.261 0.361 0.22 0.21 0.695 0.828 0.20 0.21 0.057 0.028 0.25 0.21 
hcv9277491 0.448 0.328 0.22 0.21 0.871 0.870 0.20 0.20 0.243 0.025 0.25 0.20 
rs7954838 0.170 0.463 0.22 0.22 1 0.526 0.19 0.21 0.044 0.034 0.26 0.21 
rs7955726 0.029 0.034 0.32 0.29 0.838 0.603 0.28 0.28 0.002 0.0006 0.36 0.28 
rs2164504 0.395 0.016 0.40 0.46 0.902 0.253 0.43 0.47 0.140 0.0016 0.37 0.45 
hcv400963 0.385 0.019 0.40 0.44 0.577 0.308 0.42 0.46 0.077 0.0005 0.35 0.44 
rs6421214 0.731 0.550 0.45 0.43 0.213 0.207 0.47 0.43 0.374 0.768 0.42 0.43 
rs10878167 0.488 0.048 0.21 0.25 0.391 0.252 0.22 0.25 1 0.015 0.19 0.25 
rs11175383 0.914 0.361 0.26 0.24 0.521 0.652 0.25 0.24 0.361 0.191 0.28 0.24 
hcv12069598 0.808 0.400 0.14 0.12 0.490 0.685 0.13 0.12 0.733 0.241 0.15 0.12 
rs10784408 0.683 0.649 0.14 0.13 0.857 0.855 0.14 0.13 0.677 0.450 0.15 0.13 
rs7976457 0.938 0.337 0.11 0.13 0.361 0.876 0.12 0.13 0.325 0.087 0.09 0.12 
hcv491186 0.546 0.398 0.25 0.25 0.824 0.414 0.25 0.25 0.537 0.540 0.25 0.26 
hcv22272931 0.654 0.610 0.24 0.25 0.835 0.855 0.24 0.25 0.668 0.404 0.23 0.25 
hcv315870 0.415 0.500 0.45 0.43 0.250 0.342 0.46 0.42 1 0.933 0.44 0.43 
rs1317532 0.143 0.432 0.48 0.46 0.159 0.379 0.48 0.47 0.551 0.758 0.47 0.46 
rs1317535 0.101 0.535 0.32 0.34 0.091 0.632 0.32 0.34 0.590 0.653 0.32 0.34 
rs6581575 0.639 0.213 0.48 0.45 0.903 0.389 0.47 0.46 0.379 0.192 0.49 0.45 
rs7972780 0.638 0.395 0.50 0.47 0.668 0.542 0.49 0.48 0.211 0.390 0.50 0.47 
rs4964110 0.334 0.262 0.09 0.10 0.249 0.274 0.09 0.10 0.900 0.420 0.09 0.10 
rs10506538 0.824 0.189 0.11 0.09 0.283 0.491 0.10 0.09 0.359 0.084 0.12 0.09 
rs7963840 1 0.917 0.37 0.38 0.950 0.965 0.38 0.38 0.940 0.787 0.37 0.37 
rs1245035 0.229 0.890 0.40 0.40 0.479 0.482 0.41 0.40 0.310 0.554 0.38 0.40 
rs1520765 0.448 0.871 0.47 0.46 0.616 0.402 0.49 0.47 0.562 0.513 0.45 0.46 
rs1619280 1 0.998 0.46 0.47 0.808 0.393 0.44 0.46 0.777 0.320 0.49 0.46 
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 Fig 4.2.1a Pearson’s χ2 in case-control studies. Significance of a peak at the 
95% confidence interval is reached at value of 3.9 with 1df.   
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Fig 4.2.1b Pearson’s χ2 in TDT association studies. Significance of a peak at 
the 95% confidence interval is reached at value of 3.9 with 1df. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2 Candidate genes on chromosome 12 
 
 
 
LOC115749 gene is one of the genes that could be a candidate gene due to the association 
in the surrounding markers. In both case-control studies and TDT association studies, the 
most significant SNP marker (rs7955726) was located in this gene. 
 
The intron-exon structure of LOC115749 gene known and yields an open reading frame 
of 444 amino acid. However, the functional of the protein is unknown. After using the 
Scanprosite program (http://us.expasy.org), several functional sites were predicted: five 
casein kinase II phosphorylation sites; eight protein kinase C phosphorylation sites; one 
tyrosine kinase phosphorylation site; one N-glycosylation site and one N-myristoylation 
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site. These potential functional sites may give some indication about the function of the 
LOC115749 gene.  
 
Another website (http://www.sbg.bio.ic.ac.uk/phyre) also used for predicting the function 
of LOC115749 gene. This protein was 95.8% identity with the XP_509192 protein, which 
similar to the ATPase, H+ transporting lysosome (Fig 4.2.2a). The ATPase plays an 
important role in IBD 126 127 128. 
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for a   Fig 4.2.2a Protein prediction by www.sbg.bio.ic.ac.uk/phyre website. 
ording to the database, this gene has 11 exons. We sequenced all the exons in a set of 
unrelated UC patients. The only exon polymorphism that was found was a 
nymous mutation. This SNP showed weak association (PTDT=0.172; 
/control=0.025) with the UC patients in case-control studies.  The most significant SNP 
55726) was located in the intron between exon 3 and exon 4 (an overview was 
n in Fig 4.2.2b). It associated with two binding sites, one for NF-E2 p45 and another 
ctivator protein 1 in its wild type.  
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The transcription factor NF-E2 is expressed in erythroid cells, megakaryocytes, and mast 
cells, and it has been shown to be a heterodimer formed between the large subunit (p45) 
and the small subunit (p18) 129 130. P45 belongs to a family of basic leucine-zipper protein 
131. The NF-E2 p45 is highly expressed in the erythroid and megakaryocytic lineages 129 
132 133. Micheal McMahon et al 134 demonstrated that the small intestine and stomach are 
organs where regulation of antioxidant responsive element (ARE)-driven genes may be 
particularly dependent on NF-E2. 
 
The transcription factors activator protein (AP) 1 and nuclear factor (NF) κB have been 
reported to be crucial for the induction of genes involved in inflammation, as well as in a 
wide range of diseases originating from chronic activation of the immune system, such as 
inflammatory bowel disease 135 136 137 138. The transcription factor AP1 is encoded by 
protooncogenes and regulates various aspects of cell proliferation and differentiation 139 
140 141. The regulation of AP1 activity is complex. Two genes (Jun and Fos) are involved 
142 143 144. Many stimuli, such as physiological agents, bacterial and viral infections, 
pharmacological compounds and cellular stress can induce AP1 activity. 
 
The most significant SNP (rs7955726) can influence these two binding sites. In the 
genotype of wild-type (G), the binding sites for NF-E2 p45 and AP1 were intact. But for 
the other genotype (T), those two binding sites were disrupted.  
 
The RT-PCR of a tissue panel showed that this gene is highly expressed in thymus. The 
thymus plays crucial role in immune system. This also might be a hint to function studies. 
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FLJ32549 gene is another candidate gene within this region. It is a known gene with 
hypothetical protein product. It contains 4 exons. One significant SNP marker 
(hcv8757644, PTDT=0.088; Pcase/control=0.0036) associated with UC patients in case-control 
study was located between exon1 and exon2. However, the TDT association studies did 
not yield the same result. All the other SNP markers in this gene did not show significant 
results. FLJ32549 gene may only have a weak effect on UC patients. 
 
BC042855 gene is the third candidate gene within this region. It has 5 exons without 
protein product. Two SNPs (rs11175286, PTDT=0.48951; Pcase/control=0.0053; rs1657050, 
PTDT=0.43858; Pcase/control=0.0034) in this gene showed significant results in UC patients in 
case-control studies. TDT gave disparate results for these two markers. 
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Fig 4.2.2b Overview of the linkage disequilibrium structure of the chromosome 12q12 
region.  
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5. Conclusions 
 
 
We use association mapping with diallelic SNP markers to refine a previously identified 
linkage region on chromosome 12. Candidate gene analysis was used for identification of 
susceptibility gene for inflammatory bowel disease on chromosome 12 and chromosome 
7. Two kinds of statistical methods were used. The case-control study is based on identity 
by state of the disease allele and the marker used for analysis in the group of independent 
cases, while the TDT association study identifies the transmission of alleles from parents 
to offspring.  
 
The AGR gene is located on chromosome 7p2.1, which is a linkage region for 
inflammatory bowel disease. Thirty SNP markers of AGR2 and AGR3 gene were 
genotyped in a German cohort and the significant SNP markers were verified in UK 
cohort. The association is most pronounced at hcv1702494 and hcv111845, which is 
located on the 5’ region of AGR2 gene for UC phenotype. Functional studies were 
performed on the AGR2 gene. Those data demonstrate association of the 5’region of the 
AGR2 gene to the UC phenotype in two independent populations. Functionally, the gene 
may be involved in the maintenance of epithelial integrity based on the mouse model, 
phylogenetic background and activation by transcription factors, which are characteristic 
for epithelial goblet cells. The disease effect is likely to be mediated through down-
regulation of the AGR2 transcript in disease, as suggested by association to individual 
promoter SNPs. The mechanistic risk profile of the risk haplotype is functionally not yet 
fully explored and possibly includes further private mutations in more distant regulatory 
elements. The impact of the risk mutations on the overall phenotype is moderate, as 
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indicated by allelic odds ratios in the range of 1.3 – 1.4. Overall, the AGR2 represents an 
interesting new avenue into the etiopathophysiology of IBD and warrants further 
evaluation in additional, independent populations.  
 
Fifty diallelic SNP markers were used to identify the inflammatory bowel disease linkage 
region on chromosome 12q. Significant results both in case-control study and TDT 
association study were obtained. These results showed strong association with UC 
subgroup.  
 
Three candidate genes were located in this region. The major disease-associated SNP 
rs7955726 was located in the intron between exon3 and exon 4 of LOC115749 gene. The 
function of LOC115749 gene is unknown. The significant SNP marker (rs7955726) 
influenced the binding site for NF-E2 p45 and AP1. This gene is highly expressed in 
thymus and the protein was 95.8% identity with the XP_509192 protein, which similar to 
the ATPase, H+ transporting lysosome. The ATPase plays an important role in IBD The 
other two candidate genes only show weak association with UC phenotype. It seems that 
LOC115749 gene might be a disease gene for UC but the mechanistic details were not 
known yet. 
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6. Summary  
 
Genome wide linkage analyses have implicated chromosome 7p21.3 and chromosome 
12q14 as a susceptibility region for IBD. Recently, the mouse phenotype with diarrhea 
and goblet cell dysfunction caused by anterior gradient protein 2 dysfunction was reported 
(European patent WO2004056858). The genes encoding for the human homologues 
anterior gradient proteins 2 and 3 (AGR2 and AGR3) are located on chromosome 7p21.3. 
The gene structures of human AGR2 and AGR3 were verified and exhaustive mutation 
detection was performed in 46 individuals with IBD. Thirty SNPs were tested for 
association to ulcerative colitis (UC, N=317) and Crohn’s disease (CD, N=631) in a 
German cohort and verified in a (UK) cohort of 384 CD and 311 UC patients. An 
association signal was identified in the 5’ region of the AGR2 gene. AGR2 was down-
regulated in UC patients as compared to normal controls. Luciferase assays of the AGR2 
promoter showed regulation by the goblet-cell specific transcription factors FOXA1 and 
FOXA2. In summary, AGR2 represents an interesting new avenue into the 
aetiopathophysiology of IBD and the maintenance of epithelial integrity. Fifty SNPs 
within chromosome 12q14 region were genotyped in a German cohort (484 with CD, 292 
with UC) to confine the region where a potential disease susceptibility gene could be 
located. The most significant SNP marker was rs7955726, which located between exon 3 
and exon 4 of LOC115749 gene. LOC115749 gene was highly expressed in thymus and 
highly identity to the ATPase proteins. Mutation detection and genotyping of LOC115749 
gene only gave weak significant results. The rs7955726 influenced the binding site of NF-
E2 and AP1. The LOC115749 gene might be a candidate gene for UC patients but the 
mechanistic details were not known yet. 
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7. Zusammenfassung 
 
 
Genomweite Kopplungsstudien haben Chromosom 7p21.3 und Chromosom 12q14 als 
Kandidatenregionen für chronisch entzündliche Darmerkrankungen (CED) identifiziert. 
Vor kurzem wurde ein Mausphänotyp mit Diarrhö und Becherzellenfehlfunktion 
beschrieben (Europäisches Patent WO2004056858), was durch eine Fehlfunktion im 
Anterior Gradienten Protein 2 verursacht wird. Die Gene, welche für die menschlichen 
Homologe der Anterior Gradienten Proteine 2 und 3 kodieren (AGR2 and AGR3), liegen 
auf Chromosom 7p21.3. Die Genstrukturen von AGR2 und AGR3 wurden verifiziert, und 
es wurde eine Mutationsdetektion in 46 Individuen mit CED durchgeführt. Die 
Assoziation von 30 SNPs mit Ulcerativer Colitis (UC, N=317) und Morbus Crohn (CD, 
N=631) wurde in einer deutschen Kohorte getestet und und in einer englischen (UK) 
Kohorte von 384 CD und 311 UC Patienten verifiziert. Es konnte ein Assoziationssignal 
in der 5’-Region des AGR2 Genes identifiziert werden. AGR2 ist in UC-Patienten 
herunterreguliert, verglichen mit gesunden Kontrollen. Luciferase Analysen des AGR2 
Promotors zeigten eine Regulation durch die Becherzell-spezifischen 
Transkriptionsfaktoren FOXA1 und FOXA2. AGR2 liefert neue Einblicke in die 
Pathogenese von CED und in die Aufrechterhaltung des epithelialem Zusammenhalts. In 
der Region auf Chromosom 12q14 wurden 50 SNPs in einer deutschen Kohorte 
genotypisiert (484 mit CD, 292 mit UC), um die Region auf ein potentielles 
Krankheitsgen einzuschränken. Der am stärksten signifikante SNP (rs7955726), 
lokalisierte zwischen Exon 3 und Exon 4 des BC039369 Genes. Das BC039369 Gen wird 
am stärksten im Thymus exprimiert und hat hohe Ähnlichkeit mit ATPase Proteinen. Die 
Mutationsdetektion und Genotypisierung von BC039369 ergab nur schwach signifikante 
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Ergebnisse. Der SNP rs7955726 beeinflusst die Bindungsstelle von NF-E2 und AP1. 
BC039369 könnte ein Kandidatengen für Patienten mit UC sein, die zugrunde liegenden 
Mechanismen konnten aber bisher nicht aufgeklärt werden.
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